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ABSTRACT

A novel method for in situ preparation of injectable biodegradable
microspheres from the copolymer poly(lactide-co-glycolide) (PLGA) without
incorporating unacceptable organic solvents is described. The delivery system is
a dispersion of PLGA microglobules ("premicrospheres" or "embryonic
microspheres") in an acceptable vehicle mixture (continuous phase) and whose
integrity is maintained by use of appropriate stabilizers. A solution of PLGA,
triacetin, drug, PEG 400, and Tween 80 (Oil Phase 1) are added dropwise with
continuous homogenization to miglyol 812-Span 80 solution (Oil Phase 2),
thereby inducing phase separation (coacervatio{) of PLGA and forming PLGA
microglobules (containing the drug) dispersed in the continuous phase. This
novel drug delivery system (NDDS) is a dispersion and has a viscous consistency
but is sufficiently syringeable. When injected, it comes in contact with water
from aqueous buffer or physiological fluid and as a result, the microglobules
harden to form solid matrix type microparticles entrapping the drug (in situ
formed microspheres). The drug is then released from these microspheres in a
controlled fashion.
This novel microencapsulation process overcomes some of the
disadvantages associated with the existing methods by: (i) excluding the use of
unacceptable organic solvents and using acceptable vehicle mixture instead to
prepare biodegradable PLGA microspheres, (ii) forming drug containing PLGA
microglobules ("premicrospheres" or "embryonic microspheres") which could be
considered as precursors to the final microsphere product; these on coming in
contact with water harden to form discreet PLGA microspheres which
subsequently exhibit non-variable, predictable, and controlled drug release profile,
and (iii) precluding the need for reconstitution of the PLGA microspheres before
their administration.
The composition, rationale, and optimization of the NDDS is described
here. The characteristics of this NDDS were affected by various formulation

varibles such as: (i) the PLGA concentration and type, (ii) the substitution of the
continuous phase by a fresh Oil Phase 2, (iii) the concentration of PEG 400 and
the encapsulated drug, (iv) the addition of an hydrophilic excipient (mannitol),
and (v) the types of encapsulated drugs and the vehicles added to the system. The
characteristics of the NDDS were reproducible and were not affected by a 15
days/4° C storage condition. Also, the formulation, process, and the storage ( 15
days/4° C) conditions did not adversely affect the physical stability of the
encapsulated proteins.
Besides producing injectable in situ formed microspheres, this novel
microencapsulation process can be modified to yield injectable in situ formed
implant or isolated microspheres. Thus this n~vel microencapsulation process is
versatile and it can produce various drug loaded injectable biodegradable PLGA
devices having different characteristics.
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PREFACE

This dissertation has been written in the Manuscript Format as per the
guidelines issued by The Graduate School at the University of Rhode [sland. This
option was most suitable to present my results in several sections.
Section I constitutes the Objectives and Introduction of this dissertation.
The manuscripts in Section II are the core of this dissertation. Section Ill consists
of the Conclusion and Final Remarks of this dissertation.
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SECTION I

OBJECTIVES

The main intention of this research project were to achieve controlled drug
delivery of micromolecules and macromolecules, such as proteins, from a novel
injectable biodegradable poly(lactide-co-glycolide) (PLGA) microsphere system.
This system would overcome some of the disadvantages associated with the
traditional methods for controlled drug delivery. On injection, the system would
come in contact with water from aqueous buffer or physiological fluid and as a
result, form solid matrix type microparticles entrapping the drug (in situ formed
microspheres); the drug would be released from these microspheres in a
controlled fashion.
The specific objectives of this research project were as follows:
(1)

To develop a novel method for controlled delivery of drugs from an in situ
forming biodegradable PLGA microsphere system.

(2)

To evaluate the effects of various formulation variables on the
characteristics of this system.

(3)

To determine the effects of formulation, process and storage conditions on
the reproducibility and stability of this system as well as the stability of
the encapsulated proteins.

(4)

To modify this novel microencapsualtion process, to produce in situ
formed implant or isolated microspheres and also compare the
characteristics of the three biodegradable devices: in situ formed implant

vis in situ formed microsphres v/s isolated microspheres.
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INTRODUCTION

To avoid inconvenient surgical insertion of large implants, injectable
biodegradable and biocompatible polymeric particles (microparticles and
nanoparticles) could be employed for parenteral controlled-release dosage forms .
Microparticles of size less than 250 µm, ideally less than 125 ~Lmare suitable for
this purpose. Biodegradable polymers are natural or synthetic in origin and are
decomposed in vivo, either enzymatically or non-enzymatically to produce
biocompatible, toxicologically safe by-products which are further eliminated by
normal metabolic pathways. Drugs formulated in polymeric devices are released
either by diffusion through the polymer barriet or by erosion of the polymer
material, or by a combination of both diffusion and erosion mechanisms. The
polymers selected for the parenteral administration must meet several
requirements like biocompatibility, drug compatibility, suitable biodegradation
kinetics and mechanical properties, and ease of processing.
Although a wide variety of natural and synthetic biodegradable polymers
have been investigated for drug targeting or prolonged drug release, only a few of
them are actually biocompatible. Natural biodegradable polymers like bovine
serum albumin (BSA), human serum albumin (HSA), collagen, gelatin, and
hemoglobin have been studied for drug delivery. The use of these natural
polymers is limited due to their higher costs and questionable purity.
In the past two decades synthetic biodegradable polymers have been
increasingly used to deliver drugs, since they are free from most of the problems
associated with natural polymers. Poly(amides), poly(amino acids), poly(alkyl-acyano acrylates), poly(esters), poly(orthoesters), poly(urethanes), and
poly(acrylamides) have been used to prepare polymeric devices to deliver drugs.
Amongst them, the thermoplastic aliphatic poly(esters) like poly(lactide) (PLA),
poly(glycolide) (PGA), and especially the copolymer oflactide and glycolide
referred to as poly(lactide-co-glycolide) (PLGA) have generated immense interest
due to their excellent biocompatibility and biodegradability. Also PLGA has been
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approved by the U.S. FDA for a number of clinical applications including surgical
sutures and as controlled-release microspheres. PLGA is shown to be
biocompatible and degrades to toxicologically acceptable lactic and glycolic acids
that are eventually eliminated from the body. Release of drugs from PLGA
microspheres occurs by two mechanisms: (i) diffusion of the drug through a
tortuous, water-filled path in the polymer matrix and (ii) matrix bioerosion (bulk
hydrolytic degradation) after undergoing sufficient hydration. The actual release
is a combination of both the processes.
There is a particular interest in controlled delivery of macromolecules like
peptides and proteins through PLGA microspheres. Although a wide variety of
pharmacologically useful peptide and protein b~ed drugs have been recently
developed by genetic engineering, their therapeutic use is restricted due to certain
disadvantages: (i) on oral consumption they are subject to attack by the acidic and
enzymatic environment in the stomach and the enzymes from the brush border
membrane of the intestine, (ii) their high molecular weight and size impede their
effective transport across the gastrointestinal membranes, and (iii) they have a
short biological half-life and on injection they are quickly metabolized and
eliminated. To achieve sustained blood levels of these drugs, minimize their
denaturation or degradation, and to extend their biological half-life, their delivery
by encapsulation in PLGA microspheres has become an interesting approach.
The literature on PLGA microspheres is full of different techniques
describing their manufacture, where the microspheres are produced in a freeflowing, powder form. Some of the methods reported are: (i) single/double
emulsification followed by solvent removal by evaporation or extraction, (ii)
phase separation (coacervation), and (iii) spray-drying. Most of these
manufacturing processes suffer from drawbacks such as: (i) the microspheres need
to be reconstituted (suspended) in an aqueous media, before they could be injected
in the body, (ii) the hazards and environmental concern associated with the use of
organic solvents like methylene chloride for the solubilization of PLGA polymer,
and (iii) residual organic solvents remaining in the final microsphere product.
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Shah et al and researchers from Atrix Laboratories, Inc. (Fort Collins, CO)
have described a novel implant system which is parenterally administered as a
liquid and subsequently solidifies into a gel matrix (implant) in situ, from which
the drug is released in a controlled manner. Although this implant system
precludes the need for any surgery for its administration, it has a number of
disadvantages: (i) the safety of solvents like N-methyl-2-pyrrolidone,

used to

formulate these systems is questionable and not well documented, (ii) the
injection of these liquid implant systems and their subsequent solidification
produce non-uniform matrix implants having variable consistency and geometry,
and (iii) due to formation of matrix implants having inconsistent texture, shape
and size, the drug release from them is variablf. and unpredictable.
The present process of microsphere formation is based on the principle of
coacervation. This method overcomes the problems faced by the above systems
by forming a dispersion of PLGA microglobules ("premicrospheres" or
"embryonic microspheres") in an acceptable vehicle mixture (continuous phase)
and whose integrity is maintained by use of appropriate stabilizers. A solution of
PLGA, triacetin, drug, PEG 400, and Tween 80 (Oil Phase 1) are added dropwise
with continuous homogenization to miglyol 812-Span 80 solution (Oil Phase 2),
thereby inducing phase separation (coacervation) of PLGA and forming PLGA
micro globules (containing the drug) dispersed in the continuous phase. This
novel drug delivery system (NDDS) is a dispersion and has a viscous consistency,
but is sufficiently syringeable. When injected, it comes in contact with water
from aqueous buffer or physiological fluid and as a result, the microglobules
harden to form solid matrix type microparticles entrapping the drug (in situ
formed microspheres). The drug is then released from these microspheres in a
controlled fashion. This novel microencapsulation method can be modified to
produce other biodegradable PLGA devices exhibiting controlled drug delivery.
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SECTION II
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MANUSCRIPT I

CONTROLLED DRUG DELIVERY BY BIODEGRADABLE POL Y(ESTER)
DEVICES: DIFFERENT PREPARATIVE APPROACHES

7

ABSTRACT
There has been extensive research on drug delivery by biodegradable
polymeric devices since bioresorbable surgical sutures entered the market two
decades ago. Amongst the different classes of biodegradable polymers, the
thermoplastic aliphatic poly(esters) like poly(lactide) (PLA), poly(glycolide)
(PGA), and especially the copolymer of lactide and glycolide referred to as
poly(lactide-co-glycolide) (PLGA) have generated interest due to their excel lent
biocompatibility, biodegradability, and mechanical strength. Also, they are easy
to formulate into various devices for carrying a variety of drug classes such as
vaccines, peptides, proteins, and micromolecules; most importantly they have
been approved by the Food and Drug Administration (FDA) for drug delivery.
This review presents different techniques of preparation of various drug
loaded PLGA devices, with special emphasis on preparing microparticles. Certain
issues about other related biodegradable polyesters are discussed.
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INTRODUCTION
A controlled drug action may be achieved by either chemically modifying
the drug moiety (e.g. prodrug) or by formulating it in a specific way to control its
release. Oral controlled-release dosage forms, depending upon the drug
employed, can provide efficacy for about 24 hr. ( 1). Oral dosage forms may not
be feasible in cases where the drug undergoes extensive degradation in the
gastrointestinal tract, exhibits significant first-pass effect, or is poorly absorbed.
Of serious concern are the problems associated with the oral administration of
peptide/protein drugs which are subject to attack by the acidic and enzymatic
environment in the stomach and the enzymes from the brush border membrane of
the intestine. Also their high molecular weig11tand size impede their effective
transportation across the gastrointestinal tract membranes. The main drawback of
oral dosage forms are the short transit time of approximately twelve hours through
the gastrointestinal tract (2). Further, if the drug is absorbed only through a
specific area of the gastrointestinal tract, the duration of action could be less than
twelve hours (2).
If a drug cannot be administered orally due to any of the above reasons, a

parenteral route of delivery is an alternative. One advantage that a parenteral
controlled release dosage form has over oral controlled release dosage forms is
patient compliance (2). Although an oral dosage form might have a good
bioavailability, a long-acting parenteral dosage form that is safe and efficacious
for days or weeks or months could be beneficial because it ensures that the patient
is receiving medication. Also a parenteral controlled release dosage form is
preferred over conventional parenteral dosage form for chronic treatment where
routine multiple injections could be inconvenient and painful. Parenteral
controlled release dosage forms are also effective in site-specific drug delivery,
thereby improving its efficacy and reducing its toxicity. The main disadvantage
of these dosage forms is that once administered, they cannot be easily removed
(2). This could be a problem for the patient if a drug was no longer needed, or
worse if it caused an undesirable reaction.
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To avoid inconvenient surgical insertion of large implants, injectable
biodegradable and biocompatible polymeric particles (microspheres,
microcapsules, nanocapsules, nanospheres) could be employed for parenteral
controlled-release dosage forms (1 ). Microparticles of size less than 250 ~tm,
ideally less than 125 µmare suitable for this purpose (2). Biodegradable
polymers are natural or synthetic in origin and are decomposed in vivo, either
enzymatically or non-enzymatically to produce biocompatible, toxicologically
safe by-products which are further eliminated by normal metabolic pathways (3).
Drugs formulated in polymeric devices are released either by diffusion through
the polymer barrier, or by erosion of the polymer material, or by a combination of
both diffusion and erosion mechanisms (4). Thl polymers selected for the
parenteral administration must meet several requirements like biocompatibility,
drug compatibility, suitable biodegradation kinetics and mechanical properties,
and ease of processing (4, 5).
Although a wide variety of natural and synthetic biodegradable polymers
have been investigated for drug targeting or prolonged drug release, only a few of
them are actually biocompatible. Natural biodegradable polymers like bovine
serum albumin (BSA), human serum albumin (HSA), collagen, gelatin, and
hemoglobin have been studied for drug delivery (1 ). The use of these natural
polymers is limited due to their higher costs and questionable purity (I).
In the past two decades synthetic biodegradable polymers have been
increasingly used to deliver drugs, since they are free from most of the problems
associated with natural polymers (1-8). Poly(amides), poly(amino acids),
poly( alky 1-a-cyano acry lates ), poly( esters), po 1y( orthoesters), po Iy( urethanes),
and poly(acrylamides) have been used to prepare polymeric devices to deliver
drugs (1-7). Amongst them, the thermoplastic aliphatic poly(esters) like
poly(lactide) (PLA), poly(glycolide) (PGA), and especially the copolymer of
lactide and glycolide referred to as poly(lactide-co-glycolide) (PLGA) have
generated immense interest due to their excellent biocompatibility and
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biodegradability (1-17). Also they are easy to formulate into drug carrying
devices and have been approved by the FDA for drug delivery use (13-17).
This review provides a comprehensive outlook on different techniques of
preparation of various drug loaded PLGA devices, with special emphasis on
preparing microparticles. Certain issues about other related biodegradable
polyesters like PLA and PGA have been discussed as well.

HISTORICAL DEVELOPMENT OF DRUG DELIVERY USING PLGA
The discovery and the synthetic work on low molecular weight oligomeric
forms of lactide and/or glycolide polymers was first carried out several decades
back (3, 5). The methods to synthesize high 1molecular weights of these polymers
were first reported by Lowe (3).
During the late 1960s and early 1970s a number of groups had published
pioneering work on the the utility of these polymers to make sutures/fibers (2, 3,
5, 12). These fibers had several advantages such as good mechanical properties,
low immunogenicity and toxicity, excellent biocompatibility, and predictable
biodegradation kinetics (2, 3, 5, 12). The wide acceptance of the lactide/glycolide
polymers as suture materials, made them an attractive candidate for biomedical
applications like ligament reconstruction, tracheal replacement, ventral
herniorrhaphy, surgical dressings, vascular grafts, nerve, dental, and fracture
repairs (3, 5, 9).
The biodegradation, biocompatibility, and tissue reaction of PLA and
PLGA have been extensively investigated and well documented by many
researchers (5, 14). The first work on parenteral controlled release of drugs using
PLA was reported by Boswell, Yolles, Sinclair, Wise, and Beck (3, 5). Since then
an ocean of literature on drug delivery using PLA, and especially PLGA has been
published. Various polymeric devices like microspheres, microcapsules,
nanoparticles, pellets, implants, and films have been fabricated using these
polymers for the delivery of a variety of drug classes.
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SYNTHESIS OF PLGA COPOLYMER
Low molecular weight PLGA can be prepared by direct condensation
(polyesterification) of lactic and/or glycolic acids (5, 12). Temperatures as high
as 130-190° C are required for the condensation process and the water generated is
removed by boiling, using vacuum, purging with nitrogen, or azeotropic
distillation with an organic solvent (3, 12). An acid catalyst like antimony oxide
increases the reaction rate if used at reaction temperatures below 120° C, but
above this temperature water removal is the rate-limiting step (3, 12). This
method yields PLGA having molecular weight of - 10,000 (12). The low
molecular weight PLGA has limited biomedical application, due to its poor
mechanical strength and faster degradation (3

f

Intermediate and high molecular weight PLGA (-10,000-40,000) can be
prepared by the ring-opening polymerization of the cyclic dimers (cyclic di ester
of lactic and/or glycolic acids) as the starting materials (3, 5, 12, 14). The
advantage of this method is that no water removal/dehydration method is needed
in the polymerization system (3). Also the cyclized monomer(s) and the linear
form of the polymers produced can be readily purified (3). Compounds of lead,
tin, cadmium, zinc, antimony, and titanium have been used as catalyst to initiate
the polymerization process (12, 14). Acid catalyzed bulk polymerization (melt
method) for two to six hours at around 175° C is generally employed for
preparation of PLGA from lactide and glycolide monomers (3). The molecular
weight of the resultant PLGA is determined by the concentration of the catalyst
added (12). Monomer purity of99.9% or greater and monomer acidity of0.05%
or less are required with the starting lactide and glycolide materials (5). Also
important are the low levels of humidity in the processing area (5).

PHYSICAL, CHEMICAL, AND BIOLOGICAL PROPERTIES OF PLGA

It is important to understand the physical, chemical, and biological
properties of the polymer before formulating a controlled drug delivery device.
The various properties of the polymer and the encapsulated drug directly
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influence other factors like the selection of the microencapsulation process, drug
release from the polymer device, etc. (1 ).
PLA can exist as the optically active stereoregular polymer (L-PLA) and a
optically inactive racemic polymer (D, L-PLA) (1, 5, 9). L-PLA is found to be
semicrystalline in nature due to high regularity of its polymer chain while D, LPLA is an amorphous polymer because of irregularities in its polymer chain
structure (3, 9). Hence the use of D, L-PLA is preferred over L-PLA as it enables
more homogeneous dispersion of the drug in the polymer matrix (9, 13). PGA is
highly crystalline because it lacks the methyl side groups of the PLA (3, 9).
Lactic acid is more hydrophobic than glycolic acid and hence lactide-rich PLGA
;,

copolymers are less hydrophilic, absorb less water, and subsequently degrade
more slowly (1, 3, 13).
The molecular weight and polydispersity index of the polymer are factors
which affect the mechanical strength of the polymer and its ability to be
formulated as a drug delivery device (3, 5, 12). Also these properties may control
the polymer biodegradation rate and hydrolysis (3, 12). The commercially
available PLGA polymers are usually characterized in terms of intrinsic viscosity
which is directly related to their molecular weights (3).
The degree of crystallinity of the PLGA polymer directly influences its
mechanical strength, swelling behavior, capacity to undergo hydrolysis, and
subsequently its biodegradation rate (3). The resultant crystallinity of the PLGA
copolymer is dependent on the type and the molar ratio of the individual monomer
components (lactide and glycolide) in the copolymer chain (I). PLGA polymers
containing 50:50 ratio of lactic and glycolic acids are hydrolyzed much faster than
those containing higher proportion of either of the two monomers (5, 12). PLGAs
prepared from L-PLA and PGA are crystalline copolymers while those from D, LPLA and PGA are amorphous in nature (3, 5). Gilding and Reed have pointed out
that PLGAs containing less than 70 % glycolide are amorphous in nature ( 18).
The degree of crystallinity and the melting point of the polymers are directly
related to the molecular weight of the polymer (3, 5).

13

The glass transition temperature (Tg) of the PLGA copolymers are above
the physiological temperature of 3 7° C and hence they are glassy in nature (3, 5).
Thus they have a fairly rigid chain structure which gives them significant
mechanical strength to be formulated as drug delivery devices (3, 5). Jamshidi et

al. have reported that Tg of PLGAs decrease with decrease of lactide content in
the copolymer composition and with decrease in their molecular weight ( 19).
It is important for the PLGA polymers to have considerable mechanical
strength since the drug delivery devices formulated using them are subjected to
significant physical stress (3, 5). Different factors like the molecular weight,
copolymer composition (lactide/glycolide ratio), crystallinity, and geometric
regularity of individual chains significantly affect the mechanical strength of the
polymer (1, 3, 5).

In vitro and in vivo the PLGA copolymer undergoes degradation in an
aqueous environment (hydrolytic degradation or biodegradation) through cleavage
of its backbone ester linkages (1-3, 5, 12, 13). The polymer chains undergo bulk
degradation and the degradation occurs at uniform rate throughout the PLGA
matrix (3, 13). Thies and Bissery have reported that the PLGA biodegradation
occurs through random hydrolytic chain scissions of the swollen polymer (20).
The carboxylic end groups present in the PLGA chains increase in number during
the biodegradation process as the individual polymer chains are cleaved; these are
known to catalyze the biodegradation process (3, 5). The biodegradation rate of
the PLGA copolymers are dependent on the molar ratio of the lactic and glycolic
acids in the polymer chain, molecular weight of the polymer, the degree of
crystallinity, and the Tg of the polymer (3, 5, 13). A three phase mechanism for
the PLGA biodegradation has been proposed (21):
1. Random chain scission process. The molecular weight of the polymer
decreases significantly, but no appreciable weight loss and no soluble monomer
products formed.
2. In the middle phase a decrease in molecular weight accompanied by rapid loss
of mass and soluble oligomeric and monomer products are formed.
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3. Soluble monomer products formed from soluble oligomeric fragments. This
phase is that of complete polymer solubilization.
The extent, if any, on the role of enzymes in the PLGA biodegradation is
unclear (3, 5). Most of the literature indicates that the PLGA bi ode gradation does
not involve any enzymatic activity and is purely through hydrolysis (3).
However, some investigators have suggested an enzymatic role in PLGA
breakdown based upon the difference in the in vitro and in vivo degradation rates
(5).

The PLGA polymer biodegrades into lactic and glycolic acids ( 1-3, 5, 12,
13). Lactic acid enters the tricarboxylic acid cycle and is metabolized and
subsequently eliminated from the body as cafbon dioxide and water ( 1-3, 5, 9). In
a study conducted using
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C-labeled PLA implant, it was concluded that lactic

acid is eliminated through respiration as carbon dioxide (22). Glycolic acid is
either excreted unchanged in the kidney or it enters the tricarboxylic acid cycle
and is eventually eliminated as carbon dioxide and water (3).

METHODS OF PREPARING VARIOUS PLGA DEVICES
[1] MICROPARTICLES
A number of microencapsulation techniques have been developed and
reported to date. The choice of the technique depends on the nature of the
polymer, the drug, the intended use, and the duration of the therapy (l, 2, 4, 5,
10). The microencapsulation method employed must include the following
requirements (1, 2, 23):
(i)

The stability and biological activity of the drug should not be adversely

affected during the encapsulation process or in the final microsphere product.
(ii)

The yield of the microspheres having the required size range (upto 250

µm, ideally< 125 µm) and the drug encapsulation efficiency should be high.
(iii)

The microsphere quality and the drug release profile should be

reproducible within specified limits.
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(iv)

The microspheres should be produced as a free flowing powder and should

not exhibit aggregation or adherence.

A.

Solvent Evaporation and Solvent Extraction Process

(1) Single emulsion process
This is essentially an oil-in-water (o/w) emulsion process. The polymer is
first dissolved in a water immiscible, volatile organic solvent; dichloromethane
(DCM) most commonly used. The drug is then added to the polymer solution to
produce a solution or dispersion of the drug particles (particle size of the drug
added to be< 20 µm) (4). This polymer-solvent-drug solution/dispersion is then
emulsified (with appropriate stirring and temperature conditions) in a larger
volume of water in presence of an emulsifier (such as poly (vinyl alcohol) (PY A))
to yield an o/w emulsion. The emulsion is then subjected to solvent removal by
either evaporation or extraction process to harden the oil droplets ( I 0). In the
former case the emulsion is maintained at reduced pressure or at atmospheric
pressure and the stirring rate reduced to enable the volatile solvent to evaporate (4,
10). In the latter case the emulsion is transferred to a large quantity of water (with
or without surfactant) or other quench medium, into which the solvent associated
with the oil droplets diffuses (4, 10). The solid microspheres so obtained are then
washed and collected by filtration, sieving, or centrifugation (4 ). These are then
dried under appropriate conditions or are lyophilized to give the final free flowing
injectable microsphere product.
It should be noted that the solvent evaporation process in a way is similar
to the extraction method, in the sense that the solvent must first diffuse out into
the external aqueous dispersion medium before it could be removed from the
system by evaporation (4, 10). The rate of solvent removal by the extraction
method depends on the temperature of quench water or other medium, ratio of
emulsion volume to quench water/medium volume and the solubility
characteristics of the polymer, the solvent, and the dispersion medium. The rate
of solvent removal by evaporation method strongly influences the characteristics
of the final microspheres and it depends on the temperature, pressure, and the
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solubility parameters of the polymer, the solvent, and the dispersion medium ( I 0).
Very rapid solvent evaporation may cause local explosion inside the droplets and
lead to formation of porous structures on the microsphere surface (10). Solvent
removal by extraction method is more faster (generally< 30 min) than the
evaporation process and hence the microspheres made by the former method are
more porous in comparison to those made from the latter method under similar
conditions (I 0).
The biggest drawback of the o/w emulsification method is poor
encapsulation efficiencies of moderately water soluble and water soluble drugs (I,
4, 10). The drug would diffuse out or partition from the dispersed oil phase into
the aqueous continuous phase and microcrystalline fragments of the hydrophilic
drugs get deposited on the microsphere surface and dispersed in the PLGA matrix
(24, 25). This would result in poor trapping of the hydrophilic drug such as
salicylic acid and initial rapid release of the drug (burst effect) (1 ). The o/w
emulsification process is therefore widely used to encapsulate lipid soluble drugs
like steroids ( 1).
To increase the drug loading of water soluble drugs, an oil-in-oil (o/o)
emulsification method was developed (1, 10, 26). A water-miscible organic
solvent like acetonitrile is employed to solubilize the drug in which PLGA or
PLA are also soluble. This solution is then dispersed into an oil such as light
mineral oil in presence of an oil soluble surfactant like Span to yield the o/o
emulsion. Microspheres are finally obtained by evaporation or extraction of the
organic solvent from the dispersed oil droplets and the oil is washed off by
solvents liken-hexane.

This process is also sometimes referred as water-in-oil

(w/o) emulsification method (1).
A number of formulation and process factors affect microsphere
formation. The main variables that influence the microencapsulation process and
the final microsphere product are: (a) the nature and solubility of the drug being
encapsulated; (b) the polymer concentration, composition, and molecular weight;
(c) the drug/polymer ratio; (d) the organic solvent used; (e) the concentration and
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nature of the emulsifier used; (f) the temperature and stirring/agitation speed of
the emulsification process; and (g) the viscosities and volume ratio of the
dispersed and continuous phases (I, 4, 5, 10).
(i) Solvents
Selection of dispersed and continuous phase is important for successful
microsphere formation and to achieve high drug encapsulation efficiencies. For
the solvent evaporation/extraction

method the dispersed phase selected should be

immiscible or only slightly miscible with the continuous phase and must have a
boiling point lower than that of the continuous phase (4 ). Bodmeier and
McGinity have shown that water miscible solvents like acetone and dimethyl
sulfoxide do not form microspheres upon emulsification (27). Typically, DCM
and water are used as dispersed and continuous phases respectively.

DCM is

widely used because it is a good solvent for the polymers and due to its high
volatility it can be easily removed by evaporation.
A major problem with the use of DCM is its potential toxicity (28).
Chlorinated solvents in general are considered hazardous to environment and
undesirable for use in manufacturing processes (28). Chern et al. have reported
the use of ethyl acetate to prepare PLGA microspheres by the solvent extraction
process (29). Sah et al. produced microspheres by a two-step extraction process
using methyl ethyl ketone (MEK) (IO times more soluble than DCM in water) as
the solvent for PLGA (28, 30). Rapid diffusion of MEK into the extraction
medium and migration of water into the oil droplets produced hollow
microspheres having volume mean diameter of 96 ~Lmand 60 to 77% drug
entrapment (28, 30). The authors concluded that water-immiscibility of the
dispersed phase is not an absolute requirement for the solvent
evaporation/extraction

process (28, 30).

For o/o emulsification method, acetonitrile (26, 31-38) is generally used as
the dispersed phase. Other solvents like acetonitrile/water mixture (24), DCM
(39), N ,N-dimethyl formamide (DMF) (40-42) have also been used. The
continuous phase consists of oils like light mineral oil (26, 33-36, 38, 39), cotton
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-seed oil (24), liquid paraffin (40-42), silicon oil (31), and machine oil (37). When
prepared by solvent extraction method, heptane has been most commonly used as
extraction medium (32-38). Thanoo et al. prepared microspheres from PLA using
DCM, glycerin, and isopropanol/water mixture as the dispersed phase, continuous
phase, and extraction medium respectively (43). The same group also reported
preparation of PGA microspheres using hexafluoroacetone, carbon tetrachloride,
and dioxan as the dispersed phase, continuous phase, and extraction medium
respectively (43).
In an article van Hamont et al. have concluded that the particle size of the
microspheres is a balance of the following two opposite actions: (a) higher
weights of the external oil phase tend to proJuce larger diameter microspheres due
to slowing of the solvent evaporation process and (b) decrease in polymeric
droplet coalescence due to increase in viscosity of the oil phase tend to decrease
the diameter of the microspheres (37).
Sometimes a solvent mixture rather than a solvent alone is employed as
the dispersed phase (43). Such a solvent mixture consists ofa water-immiscible
solvent such as DCM (44, 45) or chloroform (46, 47) and a water-miscible solvent
like acetone (44, 46, 47), methanol (45), ethanol (4), or propylene glycol (4). The
water-miscible solvent provides rapid solvent removal and faster polymer
precipitation and hardening (44-47). Coombes et al. used DCM-acetone mixture
in the solvent evaporation process and concluded that solvent removal process is
rapid and causes entrapment of the stabilizer molecules by physical chain
entanglement and thus enhancing their stabilizing capacity (44). Use of DCM
alone, however, results in a slow solvent evaporation process, allowing entrapped
stabilizer molecules to diffuse out into the external aqueous phase with
consequent loss of their stabilizing capacity (44). Thanoo et al. have prepared
PLGA microspheres using a mixture of two water-immiscible solvents, DCM and
chloroform by the solvent evaporation process (43). Po lard et al. have reported
that due to poor solubility of morphine in DCM, and good solubility in methanol,
methanol was used as hydrophilic cosolvent (45). As the fraction of methanol
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was increased in the DCM/methanol mixture, more morphine dissolved in the
organic phase and this enhanced the drug entrapment in the microspheres as a
result of faster precipitation of the polymer (45). However when percentage of
methanol in the solvent mixture exceeded 60%, the polymer could not be
dissolved (45). Spenlehauer et al. employed DCM:cyclohexane ( I 0: 1) mixture
for producing PLA microspheres (48). Cyclohexane is less volatile than DCM
and hence evaporation of DCM from the emulsion droplets leads to entrapment of
cyclohexane in the microspheres, resulting in formation of porous surface
structures during the final removal of cyclohexane (48).
Sansdrap and Moes have found that the increase in the external aqueous
phase volume did not affect the final microsphe/e size while increase in the
dispersed DCM volume decreased the size with narrow size distribution due to the
decrease in the viscosity of the internal phase with increasing volume (49).
(ii) Emulsifiers
During the solvent evaporation/extraction process, there is a gradual
decrease in the volume and subsequent increase in the viscosity of the dispersed
oil droplets (4). This affects the droplet size equilibrium and the droplets tend to
coalesce and produce agglomerates during the early stages of solvent removal ( 1,
4, 10). This problem could be rectified by adding a small quantity of a droplet
stabilizer (emulsifier) in the continuous phase (1, 4, 10). The emulsifier provides
a thin protective layer around the oil droplets, and hence reduces their coalescence
and coagulation (10). As the solvent is removed, the emulsifier continues to
maintain the spherical shape of the oil droplets and prevents their aggregation,
until the microspheres are hardened and isolated as discrete particles (4 ).
The physicochemical properties and the concentration of the emulsifier
strongly influences the microsphere size, shape, and drug encapsulation
efficiency. The emulsifiers most commonly used in the solvent
evaporation/extraction process are the hydrophilic polymeric colloids and/or
anionic or nonionic surfactants (4, 10). PV A is by far the most commonly used
emulsifier (25, 29, 30, 33-35, 45-47, 50-63) in the o/w emulsion method. Others
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include poly vinyl pyrrolidone (PVP) (4), alginate (4), gelatin (4), methyl
cellulose (MC) (25, 51, 54, 64, 65), hydroxyalkyl cellulose (4, 10),
Hydroxypropylmethyl

cellulose (HPMC) (49), polyoxyethylene derivatives of

sorbitan fatty esters (Tweens) (4, 10), cetyltrimethyl ammonium bromide (4, I 0),
and fatty acid salts like sodium oleate (43, 66-68). For o/o method, oil soluble
emulsifiers such as polyoxyethylene fatty ethers (Brijs), Spans, and lecithins have
been used ( 1, 4, 10).
The appropriate type and concentration of the emulsifier for a particular
process is apparently commonly determined by trial and error basis, although
optimization techniques clearly have potential in this area. For most of the
emulsifiers, the microsphere size decreases with 1ncrease in emulsifier
concentration (4, 49). Beyond a certain concentration, the emulsifier is
ineffective, due to achievement of an optimal packing concentration for the
emulsion, i.e. condensed mono layer (40). Wakiyama et al. have investigated the
emulsifying action of sodium alginate in comparison with gelatin and have
concluded that sodium alginate produced a relatively more viscous aqueous phase
and hence yielded relatively smaller microspheres as compared to those produced
by the same amount of gelatin (69). Fong et al. found that when sodium
hydroxide was added to the aqueous continuous phase, the ionization of the
emulsifier sodium oleate was increased, which resulted in higher drug
encapsulation efficiencies and smaller, spherical, but highly porous microspheres
(70). Jalil and Nixon studied the effects of oil soluble emulsifiers (Spans and
Brijs) on the size of microspheres prepared by o/o emulsion and concluded that
more hydrophilic emulsifiers produced smaller microspheres (71 ). Coombs

el

al.

prepared PLGA microspheres using various grades of poly(oxyethylene)poly(oxypropylene)

(PEO-PPO) co-polymers as the surfactants (44). The solvent

removal led to entrapment of these surfactant molecules by physical chain
entanglement and their location at the microsphere surface. The authors stated
that the PEO-PPO chain length, structure, and conformation influenced the
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surface coverage of the micro spheres, the strength of surfactant attachment, and
its overall performance (44 ).
Some times a combination of emulsifiers have been used to achieve the
necessary emulsifying action (25, 51, 72). Cavalier et al. have reported that a
combination of PV A and MC yielded PLA microspheres having maximum
sphericity and drug entrapment as compared to formulations that used these
individual colloids alone (25). This was due to improvement in the rheological
properties of the combined emulsifiers as compared to their properties when used
alone. A similar finding was reported by Spenlehauer et al. When the theoretical
drug loading ranged from 0-30%, 0.25% aqueous PV A solution gave

/

microspheres in the size range 25-50µm (51). However, for drug loading in the
range of 50-60%, 0.25% MC or a PVA:MC (50:50) mixture was necessary to
produce the micro spheres (51 ).
(iii) Polymer
The polymer type, its molecular weight, and the concentration used
strongly influence the characteristics of the final microspheres. Cavalier et al.
have reported that a decrease in PLA concentration (increase in drug/PLA ratio)
resulted in higher drug content in the microspheres (25). The same group also
reported slightly higher drug content for PLGA (65:35) microspheres against
those for PLA microspheres (25). Coombes et al. have reported a decrease in
polydispersity and particle size of the microparticles as the PLGA concentration
in it was decreased (44). In a study, drug content of PLA (molecular weight
2000) microparticles was higher than PLGA (molecular weights 9000 and 12000)
and PLA (molecular weight 9000) microparticles due to the rapid rate of polymer
precipitation at the droplet surface (45). The particle size increased from 1.0 µm
for PLGA (RG 505), to 1.1 µm for PLGA (RG 858), to 1.5 mm for PLA (R 208)
microspheres (73). The drug entrapment was however same for RG 505 and R
208 (2.8% w/w) while for RG 858 it was slightly higher (3.2% w/w) (73). ln
another study, microspheres prepared from 16% w/w PLGA had many structural
defects while those prepared from 5.3% w/w had little structural defects but were
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aggregated and formed lumps (40). Inspite an increase in the PLGA molecular
weight from 6600 to 19000, microspheres with uniform particle size and no
structural defects were produced (40). Udupa and Chandrashekar have reported a
decrease in drug content and increase in microsphere size with increase in
PLGA/drug ratio. In a peptide adsorption study, Calis et al. found that with
increase in microsphere concentration (and hence PLGA concentration) the time
for maximum peptide adsorption decreased (66). Delgado et al. have reported
that values of certain polymer parameters like polydispersity and degradation
index (a measure of polymer erosion) are directly related to the weight average
molecular weight (M,J of the PLA polymer used for microencapsulation (61 ).

i

(iv) Drugs

The biggest disadvantage of the o/w emulsification method is poor
encapsulation of water soluble drugs (1, 4, 10). The o/w emulsification process is
therefore recommended to encapsulate lipid soluble drugs ( 1). Several
investigators have tried various modifications of the o/w method to minimize
partitioning and thereby increase the entrapment of water soluble drugs (74 and
more). Bodmeier and McGinity achieved higher entrapment of ionizable drugs
like diazepam and quinidine by using high pH external aqueous phase (pH 12),
where the loss due to ionization of these drugs was reduced (74). Similarly,
Wakiyama reported higher drug encapsulation efficiencies for butamben and
dibucaine when the aqueous phase consisted of 1% alkali (high pH solution) (69).
However tetracaine under similar conditions got ionized and exhibited poor drug
entrapment (69). Polard et al. used an external phase having a pH of 9 to prevent
the solubility of morphine in water and thereby reducing its partitioning in the
external aqueous phase (45). Contrary to these results, Vaughan et al. have
reported that increasing the pH of the external aqueous phase to 10, did not
increase the loading efficiency of lidocaine (33).
The loss of drug can also be minimized by presaturating the aqueous or
organic phase with the same drug. The drug content of quinidine in PLA
microspheres increased with increase in quinidine content in the dispersed organic
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-phase (74), while tetracaine entrapment increased with prior saturation of the
aqueous phase (69).
Sah et al. have reported that the encapsulation efficiency of PLGA
microspheres decreased with increasing theoretical loading of the drug
(progesterone) due to rapid partitioning of the drug in the external aqueous phase
from the dispersed organic phase (which contained MEK) (30). Polard et al. have
shown that with increase in drug loading, the drug content of the microspheres
increased but their encapsulation efficiencies and the microsphere recovery yield
decreased (45). Also drug entrapment was higher when the drug was present in
suspension form as compared to when present in the solution form (45). A similar
result was reported by Cavalier et al., whe/e an increase in the drug/polymer ratio
resulted in increase in the drug content of the microspheres (25). Thanoo et al.
have shown an increase in the drug incorporation efficiency and the microsphere
yield with increase in the theoretical drug loading (43).
Rosilio et al. have reported that for progesterone loading of 0-30%, the
microsphere (prepared by o/w method) size was in the range 25-50 ~Lm,and for
35% loading it increased to 50-75 µm (51 ). A different observation was made by
Tsai et al. who prepared microspheres by o/o method (26). Inspite an increase in
the drug loading from 3.65 to 13.80 %, the microspheres exhibited an average size
of 95 µm, with a relatively narrow size distribution (26). In another study, an
increase in nifedipine (a water insoluble drug) loading resulted in subsequent
increase in its content in the PLGA microspheres but did not influence the mean
particle size (49).
Calis et al. carried out peptide adsorption studies and concluded that in
dilute peptide solutions, peptide-PLGA interaction favored monolayer adsorption
which fitted the Langmuir adsorption, while at higher peptide concentration,
peptide-peptide interaction are favored, resulting in multilayer adsorption which
fitted the Freundlich model (66). In another study, Duggirala et al. have showed
that with increased protein loading, the adsorption of protein on PLGA
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microspheres increased upto a definite value and then remained constant due to
saturation of the microsphere surface (monolayer coverage) by the protein (75).
Bodmeier and McGinity have shown by a Scanning Electron Microscopy
(SEM) study that for PLGA microspheres, the surface changed from a smooth
texture at low drug content to a porous honey-comb like structure at higher drug
loading (74). In another study, PLGA microcapsules containing 8% progesterone
showed a smooth external morphology while those containing 21 % drug exhibited
textured and irregularly shaped surface features (30). When the theoretical
progesterone loading was increased from 10 to 50%, the microsphere surface
changed from a smooth, uniform appearance to an irregular surface containing
well-defined progesterone crystals and numertus pores (51 ).
In a study carried out by Benoit et al., increase in the encapsulated drug
amount resulted in a gradual decrease in the Tg of PLGA polymer from 48.3 to
12.9° C (52). The authors concluded that the drug was molecularly dispersed in
an amorphous form in PLGA (formation of a stable solution) and thus strongly
plasticized the polymer (52). A similar interaction phenomena between the drug
and PLGA has been reported by Crossan and Whateley (53) and Richey and
Harris (76). Rosilio et al. have concluded that below 35% loading, progesterone
is molecularly dispersed in the PLGA glass (51 ). At 35% and above, crystal
domains of the steroid appeared and two crystalline forms, a and

~

could be

detected (51). Bodmeier and McGinity (74) and Cavalier et al. (25) have also
reported similar results of a molecular dispersion of the drug in the polymer glass.
(v) Process
Sah et al. prepared microspheres by a two-step extraction-hardening
process using MEK as a solvent for the PLGA polymer (external aqueous phase
was presaturated with MEK) (28, 30). In the first step, the emulsion was
transferred into 250 ml of aqueous PV A solution where MEK was extracted out
(30). In the next step the microcapsules were transferred into 500 ml of aqueous
PV A solution for complete hardening of the microcapsules. The authors
concluded that the initial extraction rate of MEK were critical for successful
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microencapsulation (30). Also, the particle size of the microspheres decreased
when increasing amount of MEK was predissolved in the external aqueous phase
before the emulsification process (28). Giordanao et al. used DCM saturated I%
PVA aqueous phase to make PLGA microspheres (56). Rosilio et al. prepared
microspheres from PLGA where the solvent (DCM) was removed by an
interrupted process (51 ). DCM evaporation was interrupted after a definite period
and the aqueous phase (continuous phase) was completely removed by several
decantation washings. The DCM evaporation was then continued until the
microspheres were obtained. This method was developed to minimize formation
of emulsifier-assisted drug crystals at the microsphere surface and to achieve
higher drug loading (51 ). Cowsar et al. producfd microspheres from PLGA by
two techniques: solvent extraction-solvent evaporation and solvent evaporationsolvent extraction (4 7). In the former case, most of the acetone was first allowed
to diffuse out from the dispersed organic phase (chloroform-acetone mixture) into
the external aqueous phase, followed by gradual evaporation of the residual
solvents to give the final microspheres. In the latter case, the o/w emulsion was
first subjected to solvent (DCM) evaporation for a certain period until semisolid
droplets were obtained and the residual DCM was removed by the extraction
process in a large volume of water. Microspheres from evaporation-extraction
process were less porous and exhibited better encapsulation than those prepared
from extraction-evaporation process (4 7).
Vaughan et al. (33, 34) and Pak et al. (35) have compared the effects of
the solvent extraction v/s evaporation process on the final rnicrosphere product.
Microencapsulation of lidocaine base by the evaporation process gave product
with an yield of 65-80%, volume mean diameter of 120-130 µm, drug content of
4-10%, smooth and non-porous surface, and only 30-70% loading efficiency (due
to solubility oflidocaine in the external aqueous phase) (3 3). The extraction
process, however yielded microspheres having lidocaine content in the range of 520%, particle size of 7-10 µm, smooth but very porous particles, and 100%
loading efficiencies (33). The authors had used the salt form of the drug
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(lidocaine hydrochloride), and not lidocaine base for the extraction process (33).
Extraction process using lidocaine base resulted in encapsulation efficiency of less
than 10% (33). The same group also reported a better product from the extraction
process for the drug ketoprofen in terms of drug content, loading efficiency,
particle size, and surface feature as against the evaporation process (34 ). Contrary
to these results, Pak et al. have reported slightly lower drug contents for PLGA
microspheres prepared from extraction process as compared to the evaporation
process (35).
Some investigators have compared the microspheres produced from the
o/o method against those produced from the o/w process (24, 39). Wada et al.
;-

have reported that o/o method gave L-PLA microspheres having smooth spherical
surface and higher drug entrapment due to reduction in partitioning of drug in the
external oil phase (24). The o/w process on the other hand gave a poor product
with drug particles sticking out from the surface and poor drug entrapment (24).
Contrary to these results, Menegatti et al. have stated that the o/w process
produced microspheres having average size of 38.4 µm with no aggregation, as
compared to the o/o method which yielded a poor product having severe
aggregation (39).
The rate of temperature rise and the operating temperature for solvent
evaporation strongly influences the microsphere product. Kyo et al. have reported
that the solvent evaporation at the rate of 0.5 and 2.0° C/min in an o/o process
yielded PLGA microspheres having many structural defects as against
evaporation at 0.2° C/min which produced fewer defects (40). Wakiyama et al.
have found that the organic solvent removal by heating at 40° C produced a
viscous aqueous phase and resulted in relatively larger microcapsules, than those
produced by removing solvent by vacuum at room temperature without any heat
(69). Tice and Gilley have pointed out that very rapid DCM evaporation would
cause DCM to boil of from the emulsion droplets, yielding microspheres with
cracks and pin-holes (76). Jalil and Nixon have stated that when temperature of
85° C were used (above the boiling point of the solvent acetonitrile), highly

27

porous microspheres, having internal honey-comb like structure were produced
(77). Van Hamont et al. found a predictable linear increase in the average PLGA
microsphere size as the temperature of the continuous oil phase (various grades of
machine oil) was increased from 20 to 30° C during the evaporation (of
acetonitrile) phase of the o/o emulsification process (3 7). This linearity was lost
as the temperature was increased from 30 to 40° C due to changes in the solubility
of acetonitrile in oil (3 7). By heating an o/w emulsion for 2 hr at 50° C, Vaughan
et al. could increase the drug loading efficiency from 20-30% to 75-85% (34).

Evaluation of hydrocortisone stability in PLA microspheres at different
temperature/time storage conditions revealed no drug degradation (25).
Generally, increasing the stirring rate dee/eases the microsphere size and
narrows the size distribution (49). Crossan and Whateley prepared PLGA
microspheres in the size range of 40-60 µm by using an overhead paddle stirrer
and stirring for four hours at room temperature (53). Modification of this system
by addition of a baffle reduced their size to 20-40 µm (53). A similar result was
reported by Bodmeier and McGinity (78). The side baffles reduced the effective
diameter of the vessel and hence lead to formation of smaller emulsion droplets.
Also, the baffles reduced the turbulence in the suspension mixture, thereby
increasing the stability of droplet suspension and the product yield. Further size
reduction (5-10 µm) was achieved by first high speed stirring (1500 rpm) for 10
min using a Silverson homogenizer, followed by magnetic stirring for 18 hr. to
enable complete evaporation of DCM (53). Rosilio et al. found out that for a drug
loading of 0-30%, a stirring speed of 480 rpm was required and for a drug loading
of 50-65%, stirring speed of 645 rpm was necessary to produce the microspheres
(51 ). Coombes et al. have stated that, increasing the stirring rate of emulsion
resulted in decrease in polydispersity of the PLGA microspheres but not in their
particle size (44).
(2) Double (multiple) emulsion process

The double emulsion process is essentially an water-in-oil-in-water
(w/oiw) method and is best suited to encapsulated water-soluble drugs like
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peptides, proteins, and vaccines, unlike the o/w method which is ideal for waterinsoluble drugs like steroids ( 1, 4, 5). A buffered or plain aqueous solution of the
drug (sometimes containing a viscosity building and/or stabilizing protein like
gelatin) is added to an organic phase consisting of PLGA and/or PLA solution in
DCM with vigorous stirring to form the first microfine w/o emulsion. This
emulsion is added gently with stirring into a large volume water containing an
emulsifier like PV A to form the w/o/w emulsion. The emulsion is than subjected
to solvent removal by either evaporation or extraction process. In the former case
the emulsion is maintained at reduced pressure or at atmospheric pressure and
stirred to enable DCM to evaporate. In the latter case the emulsion is transferred
to a large quantity of water (with or without su~factant) with stirring, into which
DCM is diffused out. The solid microspheres so obtained are then washed and
collected by filtration, sieving, or centrifugation. These are then dried under
appropriate conditions or are lyophilized to give the final free flowing
microsphere product.
Some groups have reported using ethyl acetate as the polymer solvent and
hydrophilic stabilizers like Pluronic F68, PEG 4600, BSA, HSA or sodium
glutamate for protein/peptide drugs (79). Singh et al. used a blend of PV A and
PVP in the outer aqueous phase to make PLA/PLGA microspheres (80). Cohen et

al. have used an outer aqueous PVA phase saturated with DCM to prepare PLGA
microspheres (81 ). Al par et al. have reported preparation of PLA microspheres in
which the inner aqueous phase contained MC besides PV A or PVP (82, 83).
They found that particles containing PVP were more hydrophobic, exhibited
higher drug loading and encapsulation efficiency, and showed decreased burst
effect as compared to those containing PV A (82, 83). The addition of a
stabilizing polymer (BSA), reduced the net encapsulation efficiency of the protein
drug (82).
A number of hydrophilic drugs like the peptide leuprolide acetate, a
luteinizing hormone-releasing hormone (LH-RH) agonist (84-89), vaccines (21,

79-81, 83, 90-124 ), proteins/peptides ( 82, 125-138), and conventional molecules
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(139-151) have been successfully encapsulated by this method. Various
formulation and process variables significantly affect the final microsphere
product and the drug release from them.
(i) The primary w/o emulsion
Ogawa et al. have concluded that the encapsulation efficiency of the drug
in PLA and PLGA microparticles increased with the increase in viscosity of the
inner aqueous phase (containing gelatin) and also by increasing the viscosity of
the whole w/o emulsion (by decreasing the amount of DCM) (84 ). The authors
concluded that the high viscosity prevented the migration of the inner aqueous
phase to the outer water phase due to local demulsification produced by the
vigorous stirring (84 ). Similar results have been /eported by Jeffery et al. who
also found an increase in the microparticle size with the increase in viscosity of
the inner aqueous phase (92). However increasing the viscosity of the inner
aqueous phase by adding PV A had no effect on the drug entrapment or the
particle size of the final microparticles (92). Jeffery et al. and others have
reported that an increase in particle size and drug entrapment was observed
following an increase in the internal aqueous phase volume (92, 118). In a study,
Crotts and Park have stated that the volume of the inner aqueous phase drastically
affected the morphology of the final microspheres and the subsequent drug release
from them; those prepared from 5.6% aqueous phase fraction were dense and nonporous while those prepared from 22.7% aqueous phase fraction were porous in
nature ( 118). Alonso et al. have reported that incorporation of a li pophilic
surfactant, L-a-phosphatidylcholine

(by dissolving it in chloroform and adding

this solution to the DCM phase) produced more hydrophobic microspheres,
causing reduction of the microsphere size and increase in particle porosity due to
better stabilization of the inner w/o emulsion (100). Other researchers have also
reported use of L-a-phosphatidylcholine

(112). In another study it was found that

a decrease in the DCM phase volume yielded particles with dense core (81 ).
The entrapment efficiency of the drug increased with decrease in drug
loading and increase in particle size (84). However other groups have found no
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relationship between encapsulation efficiency and drug loading (92, 104). Jeffery
et al. have reported that an increase in the antigen/PLGA ratio resulted in increase

in drug entrapment by PLGA and a small increase in the mean particle size of the
final microparticles (92). Also an SEM analysis revealed that at low
antigen/PLGA smooth particles were produced but at higher ratios the particles
were pitted and some particles had collapsed (92). The authors attributed this to
high surface concentration of antigen which became soluble in the surrounding
external phase, leaving a pitted surface and in some cases this caused the
microparticles to collapse (92). In another study small particles were produced
when the volume ratio of DCM to PLA was low (84 ).
Jeffery et al. have reported the effect

of hydrophobicity

(molecular weight)

of the polymer on the entrapment of the antigen; more hydrophobic (high
molecular weight of 53K) PLGA, showed relatively lower entrapment levels of
the drug than less hydrophobic 22K PLGA (92). However, Alonso et al. found no
relationship in the encapsulation efficiency with respect to polymer composition
(PLA v/s PLGA) and molecular weight (3K v/s 100K) (79). Okada et al. have
reported that an increase in the content of water-soluble oligomers (free acid
content) in PLA resulted in increase in the burst release of the encapsulated drug
(87). Also increase in the Tg of the PLA and PLGA microspheres was observed
with increase in drug loading (87). Alonso et al. have pointed out an increase in
the microparticle size with increase in the molecular weight and the concentration
of the polymer (79, 100). In a study, Benoit et al. found that microparticles
prepared from PLGA were relatively larger and exhibited higher drug entrapment
efficiency as compared to those prepared from PCL (124). Hilbert et al. used an
aqueous liposomal suspension as the inner aqueous phase and prepared
microencapsulated liposomes (109). These showed an higher burst effect as
compared to the normal microspheres due to amphiphilic nature of the
phospholipids which generated porous matrix surface ( I 09). Sah et al. have
reported that microcapsules containing PLA5000 (molecular weight 5000) or
PLGA5000 (molecular weight 5000) into PLGA 75:25 microcapsules exhibited
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increased degradation rates as compared to those containing PLGA 75 :25 alone
(117, 119, 120). The authors found that PLA5000 plasticized PLGA 75:25 and
facilitated its faster degradation (120). Other groups have also reported the effect
of PLGAs having different molecular weight and lactide/glycolide ratio on the
final microparticle size, drug entrapment, and the degradation rate of the polymer
(94, 106).
Microparticles loaded with greater amount of drug, gave a greater burst
release of the drug due to increase in the number of channels formed by the
hydrophilic drug (84, 87, 120). In a study, Alonso et al. have reported that the
microparticles prepared by the double emulsion method (drug dissolved in the
inner aqueous phase) produced more regular mi/rospheres with better control over
drug release, than those prepared by powder dispersion method (drug powder
dispersed in DCM phase) (100). Reich has noted that the encapsulated protein
drugs decrease the interfacial tension between the inner aqueous phase and the
DCM phase of the o/w emulsion (123). The properties of the protein drug has a
substantial effect on its entrapment and release thus leading to a different
optimum for different protein/polymer combinations (123).
Cohen et al. have reported that for microspheres in which the inner
emulsion was prepared using low shear (e.g. vortex mixing), the particles were
large in size and the drug encapsulation was low as compared to microspheres in
which the inner emulsion was prepared using high shear (e.g. probe sonication)
which yielded smaller particles with higher encapsulation efficiency (81 ).
However Sah et al. reported no effect of the shear rate (to prepare the o/w
emulsion) on the encapsulation efficiency and the final particle size of
PLA/PLGA microcapsules; particles prepared from low shear rate were however
more porous than those prepared from high shear rate (116).
(ii) The double w/o/w emulsion
In a study Ogawa et al. have reported that smaller microparticles were
produced when the mixing speed during emulsification of the w/o emulsion into
the double w/o/w emulsion was increased (84). A similar result was reported by
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Uchida and Goto, who also found a decrease in the drug loading efficiency with
increase in the stirring rate (105). Also an increase in the external phase volume
led to a decrease in the particle size of the microparticles (84 ). Jeffery el al. have
reported an increase in the drug entrapment and the particle size with increase in
the external aqueous phase volume (92).
Jeffery et al. found a reduction in particle size as the concentration of PY A
increased in the external aqueous phase; the entrapment of the drug was however
not affected (92). The authors attributed this to unstable emulsion droplets at low
PV A concentration resulting in formation of larger microparticles as compared to
those prepared from high PV A concentration (92). Singh et al. investigated the
residual PV A content in PLGA microparticles {nd concluded that various process
parameters like volume and concentration of the aqueous PY A solution and the
number of washes in the microencapsulation process could control the residual
levels of PV A within the acceptable limits (99).
Alonso et al. have compared microsphere preparation by two methods in
which the final organic solvent (DCM) was removed by evaporation and by
extraction into 2% aqueous isopropanol solution; no major difference was found
in the physical characteristics and the controlled drug release properties of the
resultant microspheres. The extraction technique however, yielded the
microspheres in only 30 min (79, I 00). Other groups have also reported use of
2% aqueous isopropanol solution to remove the solvent (113).
(iii) Drugs
Researchers at Takeda Chemical Industries have reported successful
encapsulation of leuprolide acetate, a luteinizing hormone-releasing hormone
(LH-RH) agonist (for treating endometriosis) into PLGA microparticles by the
double emulsion method (84-89). A pseudo-zero order release profile (for I
month) after administering PLGA loaded leuprolide acetate in rats through s.c.
and i.m. routes (85, 86, 88) and a three-month release profile following a s.c.
injection (87) has been reported by these researchers.
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There is a lot of interest in delivering vaccines through PLA/PLGA
microparticles and immense literature has been published on this aspect ( 13, I 6,
28,30,32-36,38,40,41,54,55,64,65,

74,100,102,

106-109, 114,142,155).

A

number of vaccines/immunogenic agents like ovalbumin (30, 32-36, 42, 64, 65,
155, 160), Dermatophagoides Pteronysinuss for hyposensitization therapy (38,
40), cholera toxin (41 ), tetanus toxoid (79, I 00, I 06, 114), ricin toxoid ( 102), HIV
vaccine (102), birth control vaccine (107, I 09), BSA (39, 54, 55, 81, 95, 124, 139,
140-143, 149, 151, 160), influenza toxin (28), rotovirus (13), adenovirus (16),
lysozyme (39), and Schistosoma mansomi against Schistosomiasis (93) have been
successfully delivered by encapsulation into PLA/PLGA microparticles. These
have been delivered by s.c., i.m., and oral route1o provide pulse as well as
sustained immune response for days, weeks, and months.
Besides vaccines, other peptide/protein based drugs and certain synthetic
drugs have also been successfully loaded into PLA/PLGA rnicroparticles by the
double emulsion method and administered for prolonged release effect (82, 125151).

B.

Phase Separation (Coacervation)
The coacervation method consists of decreasing the solubility of the

encapsulating polymer by addition of a third component to the polymer solution
in an organic solution (1, 4, 5). At a particular point, the process yields two liquid
phases (phase separation): the polymer containing coacervate phase and the
supernatant phase depleted in polymer. The drug which is dispersed/dissolved in
the polymer solution is coated by the coacervate. Thus the coacervation process
includes the following three steps: (i) phase separation of the coating polymer
solution, (ii) adsorption of the coacervate around the drug particles, and (iii)
solidification of the microspheres ( 152).
First, the polymer is dissolved in an organic solution. The water-soluble
drugs like peptides and proteins are dissolved in water and dispersed in the
polymer solution (w/o emulsion). Hydrophobic drugs like steroids are either
solubilized or dispersed in the polymer solution. An organic nonsolvent is then
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added to the polymer-drug-solvent system with stirring which gradually extracts
the polymer solvent. As a result the polymer is subjected to phase separation and
it forms very soft coacervate droplets (size controlled by stirring) which entrap the
drug. This system is then transferred to a large quantity of another organic
nonsolvent to harden the microdroplets and form the final microspheres which are
collected by washing, sieving, filtration, or centrifugation, and are finally dried (4,
152).
The phase separation method, unlike the o/w emulsification method is
suitable to encapsulate both water-soluble as well as water-insoluble drugs, since
its a non-aqueous method. However the coacervation process is mainly used to
encapsulate water soluble drugs like peptides, ~roteins, and vaccines. The
addition rate of first nonsolvent should be such that the polymer solvent is
extracted slowly, so that the polymer has sufficient time to deposit and coat
evenly on the drug particle surface during the coacervation process (4 ). The
concentration of the polymer used is important as well, since too higher
concentrations would result in rapid phase separation and nonuniform coating of
the polymer on the drug particles. Due to absence of any emulsion stabilizer in
the coacervation process, agglomeration is a frequent problem in this method (4 ).
The coacervate droplets are extremely sticky and adhere to each other before the
complete phase separation or the hardening stages of this method. Adjusting the
stirring rate, temperature, or the addition of an additive is known to rectify this
problem (4).
Unlike the solvent evaporation/extraction process, the requirement of
solvents for the polymer are less stringent since the solvent need not be
immiscible with water and the boiling point can be higher than that of water (4 ).
DCM, acetonitrile, ethyl acetate, and toluene have been used in this process (152163). The nonsolvents affect both the phase separation and the hardening stages
of the coacervation process. The nonsolvents should not dissolve the polymer or
the drug and should be miscible with the polymer solvent (152-160). The second
nonsolvent should be relatively volatile and should easily remove the first viscous
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nonsolvent by washing. Some of the oils used as the first nonsolvent are silicone
oil, vegetable oils, light liquid paraffin, low molecular weight liquid
polybutadiene, and low molecular weight liquid methacrylic polymers (4, 152163). Examples of the second nonsolvent include aliphatic hydrocarbons like
hexane, heptane, and petroleum ether (4, 152-163).
In the coacervation process the phase equilibrium is never reached and
hence the system is constantly out of equilibrium (4). Therefore the formulation
and process variables significantly affect the kinetics of the entire process and
ultimately the characteristics of the final microspheres. In a classic article, N ihant

et al. have investigated the effect of several process factors on the coacervation
process (152). With increase in the aqueous phaseforganic phase volume ratio
from 0.02 to 0.12% w/w the 'stability window' (an area in the phase diagram
where the dispersed aqueous phase is efficiently coated by the coacervate) was
unmodified and only got slightly narrower ( 152). An SEM picture revealed that
the morphology of the particles changed from a spherical shape for 0.02 ratio to a
deformed one at higher ratio of 0.12. Above water contents of 0.12, the
microspheres became brittle and spontaneously released the encapsulated drug
solution during filtration ( 152). With decrease in the stirring rate from 800 to 400
rpm for the aqueous drug dispersion in PLGA/DCM solution, the particle size
increased from 40.0 to 51.5 µm and for 300 rpm no microparticles were formed
(152). Similarly with decrease in the stirring rate from 200 to 130 rpm for the
phase separation by adding silicone oil, the particle size increased from 40.0 to
58.0 µm and for 100 rpm no microparticles were formed. For the addition rate (of
silicone oil) of 18 ml/min microparticles of the size 40.0 µm were formed and
their size decreased to 39.1 µm when the addition rate was decreased to 5.7
ml/min (152). However, with further decrease in the addition rate to 0.65 ml/min,
the particle size increased to 53.1 µm and aggregates were formed and in certain
cases no microparticles were formed. The authors concluded that
microencapsulation by coacervation is a complex process that depends on the
interplay of several kinetic parameters (152). In another paper, the same group
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has reported the effects of weight, volume, composition, and viscosity of the
coacervate and supernatant phases on the size distribution, surface morphology,
and internal porosity of the final microparticles ( I 62).
Other groups have also reported microencapsulation by coacervation (153161, 163). Vidmar et al. induced phase separation of a drug-PLA-DCM
suspension by addition of n-heptane to give particles in the range of 50-500 ~Lm
and in another study they used chloroform instead of DCM to dissolve the
polymer (1 ). Nakano et al. used an ethyl acetate solution of PLA/carboxymethyl
ethyl cellulose blend and suspended the drug particles in it prior to inducing phase
separation by adding ethyl ether to finally give smooth microspheres having mean
size of 16.4 µm (1). Fong et al. carried out mi&oencapsulation at low
temperature, where the drug was suspended in PLA/toluene solution at -65° C and
phase separation was induced by dropwise addition of isopropanol with constant
stirring to yield microspheres in the range of 25-50 µm (164 ). Manda! et al.
added the suspension of water soluble diltiazem or metoprolol in PL GA/DCM
solution to a silicone oil:DCM solution (1 :6 ratio) with stirring and the
coacervates obtained were hardened by petroleum ether to yield microspheres
with high encapsulation efficiencies (153). In an article, Ruiz et al. have
concluded that the polymer properties such as hydrophobicity or chain length,
viscosity of the silicone oil used, the concentration of the polymer, and the
polymer solvent/silicone oil ratio greatly affected the overall coacervation process
and thereby the characteristics of the final microsphere product ( 165).
Leelarasamee et al. have reported preparation of PLA microcapsules by solvent
partitioning to achieve phase separation ( 159). A solution of hydrocortisone and
PLA in DCM was slowly injected into a mineral oil stream with a constant
injection rate and needle size. As DCM partitioned into the mineral oil phase, the
polymer precipitated and encapsulated the drug. The microcapsules were finally
washed with hexane and they had a size of 250 µm with 90% yield (159).

C.

Spray Drying
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Injectable biodegradable PLA and PLGA microparticles have been
successfully prepared by double emulsion and phase separation as discussed in the
previous sections. The coacervation method tends to produce particles which are
agglomerated, there is difficulty in mass production, the method requires large
quantities of organic solvent, and it is difficult to remove residual solvents from
the final microsphere product (166). The double emulsion method, on the other
hand, requires many steps, rigid control of the temperature and viscosity of the
inner w/o emulsion, and is difficult to encapsulate higher concentration of
hydrophilic drugs (1, 166). Contrary to these methods, the spray drying method is
very rapid, convenient, easy to scale-up, involves mild conditions, and is less
dependent on the solubility parameter of the drug and the polymer ( 1, 166, 167).
Wise et al. reported the preparation of PLGA microcapsules in which, a
solution of PLGA, hexafluro-2-propanol, benzene, and the drug was sprayed to
produce particles ofless than 125µm (168). Bodmeier and Chen prepared
microspheres by spray drying where a water soluble drug (theophylline) was
suspended or a water-insoluble drug (progesterone) was dissolved in a PLA/DCM
solution and then spray dried to produce particles of less than 5 µm ( 169). Due to
incompatibility of the hydrophilic drug and PLA, needle shaped crystals grew on
the microsphere surface, while the progesterone-PLA solution gave smooth
particles. The nature of the solvent used, temperature of the solvent evaporation,
and presence of PLA microspheres during the spray drying process affected the
polymorphic form of progesterone. A major problem encountered with this
technique was the formation of fibers due to insufficient force available to
breakup the polymer solution. An efficient dispersion of the filament into
polymer droplets was dependent on the type of polymer and the viscosity of the
spray solution. Other groups have also reported successful preparation of PLGA
and PLA particles using the spray drying technique (167, 170-174).
Wagenaar and Muller spray dried a solution of the polymer, DCM, and the
drug piroxicam to yield microspheres which were hollow (no solid core) (167).
DL-PLA microparticles were more spherical and smooth than those made from
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DL-PLGA. The microspheres were in the size range of 1 to 15 µm, with an high
drug encapsulation efficiency of 99.0% (167). Men et al. have shown that PLGA
microparticles prepared using spray drying technique produced particles in the
size range of 1 to 15 µm and drug loading of 4.4 to 6.6 ug/mg microspheres, while
PLA microspheres prepared using coacervation technique yielded particles having
diameter in the range of 20 to 90 µm with relatively low drug loading of 3.5
ug/mg microspheres (173). In order to protect an hepatitis vaccine from the
harmful effects of the solvent, a mixture of the antigen powder and an hydrophilic
polymer, Hydroxypropyl cellulose (HPC) was first spray dried to produce core
microparticles (174). These were then suspended in PLGA/ethyl acetate solution
and spray dried to yield double walled microparticles in the size range of 4 to 22
µm. The first coating layer of HPC protected the antigen from solvent during the
second encapsulation process with PLGA (174).
Spray drying method might cause a significant loss of the product due to
adhesion of the microparticles to the inside wall of the spray drier apparatus, and
can also produce agglomeration of the microparticles (166). In order to rectify
these problems, a novel double-nozzle spray drying technique was developed
which involved use of mannitol as an anti-adherent (166). A solution or a
dispersion (w/o emulsion) of the drug in PLGA solution was sprayed from one
nozzle and from another nozzle an aqueous mannitol solution was sprayed
simultaneously and the process completed to give the final microspheres. The
surface of the spray dried microspheres were coated with mannitol and the extent
of agglomeration was decreased (166). Also this method produced microspheres
with higher yield and encapsulation ratio as compared to those prepared from the
double emulsion method (166).
D.

Miscellaneous Methods
Drug-free microsphere preparation by an interfacial deposition technique

has been described by Makino et al. (175). First, 50 ml of n-hexane was
emulsified in 1.5% w/w aqueous Pluronic F68 solution to yield an o/w emulsion.
Then 20 ml of 1.5% w/v solution ofD,L-PLA or L-PLA in DCM was added
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dropwise to the emulsion with stirring, resulting in precipitation of the polymer
and formation of 1.5 µm size microcapsules on complete solvent evaporation
(175). Wichert and Rohdewald have prepared microparticles by a new melting
method (176). The polymer D,L-PLA (molecular weight 2000 or 16,000) was
first melted in presence of the drug vinpocetine at 180° C, to obtain a
homogeneous mixture. This was then emulsified in a hot aqueous Tween 80
solution. Microspheres were obtained from this emulsion by either centrifugation
or spray drying. For the first method, the emulsion was poured into an ice water
and the suspension subsequently centrifuged and the particles obtained were then
lyophilized. For the second method, PVA was added to the hot emulsion and the
emulsion then spray dried to obtain the final microparticles. The particle size
depended on the molecular weight of the polymer and the isolation method and
were found to be in the range of 2-22 µm. The authors also found that during the
microparticle preparation, the molecular weight of PLA reduced by 12% (176).
A novel low temperature method for preparing PLA and PLGA
microspheres has been reported by Khan et al. (177) and the group at Alkermes,
Inc. (178, 179). First the protein powder and optional excipients were suspended
in the PLA/PLGA solution in acetone, ethyl acetate, or DCM. This suspension
was then sprayed into a vessel containing liquid nitrogen overlaying a frozen
extraction solvent like ethanol. The liquid nitrogen evaporates, allowing the
polymer solvent from the frozen droplets to be extracted by, liquid ethanol, now
turned liquid. Microspheres were then filtered and the residual solvents
evaporated. The microspheres were 50-60 µmin size with drug encapsulation
efficiency more than 95% (177-179). Sam et al. have described a new spray
desolvation method using non-toxic solvents ( 180). The micronized drug was
first suspend in a PLGA solution in acetone. This suspension was then atomized
ultrasonically in an ethanol bath to induce coagulation of droplets. After 30
minutes, ethanol was replaced by water to cause hardening of PLGA, and the
microparticles so formed were then collected and dried under vacuum. The
volume average diameter of the microparticles was 77 µm with drug
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encapsulation efficiency of 30-60% for water-soluble hexapeptides and 90% for
water-insoluble estradiol ( 180).
Iwata and McGinity have reported preparation of multi-phase
microspheres of D,L-PLA and D,L-PLGA containing water-soluble drugs ( 181,
182). An aqueous drug solution containing gelatin and Tween 80 was emulsified
into soybean oil containing aluminum monostearate and Tween 80 (o/w
emulsion). This was dispersed in PLA/PLGA solution of acetonitrile to form the
double w/o/"w" emulsion. This was then dispersed in light mineral oil containing
Span 80 to form the w/o/"w"/o multiple emulsion which was then agitated to
evaporate and remove acetonitrile. The hardened microspheres were filtered and
washed with n-hexane and water and finally dried under reduced pressure.
Encapsulation efficiencies of 80-100% were obtained by this method and were
higher as compared to microspheres made by the conventional o/o-solvent
evaporation method, where the drug partitioned in the polymer-acetonitrile phase
(181, 182).
To delay the release of protein from PLGA microspheres and to maintain
its biological activity, Madiba and Wu et al. combined the PLGA microspheres
with BSA loaded liposomes (183). The authors first prepared protein loaded
liposomes consisting of I :2 molar ratio of cholesterol and
dioleolyphosphatidylcholine.

Then a 6% w/w PLGA (75:25) solution in ethyl

acetate was made. The above liposome suspension was added to the polymer
solution and the mixture homogenized to produce a w/o emulsion. This emulsion
was then transferred to 85 ml of 3% w/v aqueous PY A solution, containing 5 ml
ethyl acetate and the mixture stirred to form the double w/o/w emulsion. The
solvent was removed by extracting twice in an ice-cold water and the
microspheres so obtained were finally filtered and dried and were found to be in
the range of 30-100 µm. The authors did not provide any information on the drug
encapsulation efficiency or the stability of the encapsulated BSA (183 ).
To prevent water-mediated inactivation of encapsulated vaccines, an oilbased PLGA microcapsules were designed, consisting of an oily core of antigen
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(tetanus toxoid), in which the protein is dispersed surrounded by an outer PLGA
shell (184). The antigen powder was first dispersed in mineral oil ( 1: 100
powder:oil ratio) and the microcapsules then obtained by the conventional o/wsolvent extraction/evaporation method. Microcapsules prepared using 50:50
PLGA had a mean size of 112 µm and an encapsulation efficiency of 63 %, while
those made from 75:25 PLGA were 129 µmin mean size with an encapsulation
efficiency of 86% ( 184). Hariharan and Price have reported encapsulation of the
protein, OVA by a novel colloidal suspension method (185). First OVA was
precipitated out of water using acetone to produce a colloidal suspension of OVA.
The water was then removed by dialysis and PLGA (50:50) was dissolved in the
acetone suspension, which was then emulsified in heavy mineral oil in presence of
magnesium stearate. Evaporation of solvent produced microspheres containing
colloidally dispersed OVA. The microspheres were 90-180 ~Lmin size and had
encapsulation efficiency of 89-94% (185). Abraham and Burgess have described
PLGA microsphere preparation using a novel rapid solvent evaporation method
(186). The drug, chlordiazepoxide and PLGA were first dissolved in DCM and
then dispersed in aqueous 0.01 % PVA solution to give an o/w emulsion. Water at
70° C was added to this mixture, thereby raising the temperature of the system
above the boiling point of DCM, causing its rapid evaporation and subsequent
formation of PLGA microspheres ( 186).
Burns et al. have described a new continuous encapsulation process for
preparation of progesterone and estradiol containing D,L-PLA microspheres
(187). The process was the same as the traditional o/w-sol vent evaporation
method, except that it had been converted from a batch mode to a more cost
efficient continuous process, which according to the authors, reduced several
problems associated with scale-up and process validation. There have also been
reports of preparation of PLA and PLGA microparticles by using supercritical
fluid (compressed carbon dioxide) extraction/expansion techniques ( 188).

[II] NANOPARTICLES
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Injectable microparticles from PLA and PLGA have been successfully
prepared to deliver drugs like peptides, proteins, and vaccines over a period of
days, weeks, or even months at a constant rate depending upon the degradation
behavior of the polymer employed. However due to their large size, it was
impossible to direct the drug to target tissues via systemic circulation or across the
mucosal membrane (11 ). Following oral administration, particles less than 500
nm can cross the M cells in the Payer's patch and the mesentery on the surface of
the gastrointestinal tract mucosa, delivering the drug to the systemic circulation
(11 ).
Nanospheres and nanocapsules could be prepared by the same methods as
those described for microparticles, except that manufacturing parameters are
adjusted to obtain nanometer size droplets (10). This is obtained by using a
relatively small ratio of the dispersed phase to the dispersion medium and a
substantially higher stirring speed (10). Song et al. have prepared PLGA
nanoparticles by o/w emulsification/solvent evaporation technique to produce
nanoparticles having size of 150 nm, drug loading of 15.5% w/w, encapsulation
efficiency of 62% and yield of 85% (190). Many formulation/process variables
affecting microsphere production also influence nanoparticle production, in more
or less the similar way. Dawson and Halbert prepared nanoparticles by the o/w
emulsification technique and used response surface methodology to determine the
effect of some variables on the size distribution of PLGA nanoparticles ( 191).
The authors found that the homogenization pressure and PLGA concentration
have a linear and thus predictable effect on both size and polydispersity of the
particles. Tween 80 concentration and the DCM (organic phase) concentration
had a greater effect on the diameter and polydispersity (191 ).
Muller et al. have described a novel method of preparing PLA and PLGA
nanoparticles (192). Magnetite (used for magnetic resonance imaging) was first
dispersed in ethanol by sonication. This dispersion was then incorporated in the
polyester polymers and the temperature slowly increased with stirring to remove
ethanol (192). Heating and stirring was continued to melt PLA/PLGA polymer to
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facilitate homogeneous dispersion of magnetite in them. After solidification of
the magnetite-containing polymer, they were grounded ( 192). PLA/PLGA
nanoparticles were then obtained by high pressure homogenization of the
magnetite-containing polymer particles dispersed in aqueous poloxamer 188
solution (192). Allemann et al. prepared PLA nanoparticles by a reversible
salting-out process using a cross-flow filtration technique which involved the use
of magnesium salts (193). A 90% drug entrapment was achieved by this method.
Niwa et al. have reported nanospheres production for indomethacin and 5fluorouracil (water- insoluble and water soluble drugs respectively) and for
nafarelin acetate (NA), a LH-RH analog by a novel spontaneous emulsificationsolvent diffusion method (194, 195). The drug and PLGA were first dissolved in
acetone-DCM mixture and then emulsified in an aqueous PY A solution using a
high-speed homogenizer (o/w emulsification). The rapid diffusion of acetone in
the aqueous phase resulted in faster deposition of polymeric film on the droplet
and yielded nanospheres less than 500 nm (194, 195). The same group also
reported nanospheres production for NA by the emulsion-phase separation
method in an oil system (196). An aqueous solution of NA was emulsified in
acetone-DCM mixture containing dissolved PLGA using a homogenizer at 15,000
rpm. To this was added a mixture of Triester oil (caprylate and caprate
triglyceride) and HGCR (hexaglycerine condensed ricinoleate), which resulted in
phase separation of PLGA. PLGA coacervates precipitated around the aqueous
emulsion droplets and were hardened by evaporation of the solvent to yield
nanospheres in the range of 500-800 nm (196). Murakami et al. have reported
preparation of PLGA latex by a method based on double coacervation of PYA and
PLGA (197). PLGA was first dissolved in a mixture of acetone and DCM,
ethanol, or methanol. This PLGA solution was then dispersed in aqueous PY A
solution with stirring (197). The latex dispersion was then freeze dried to obtain
powder latex having size of approximately 300 nm. The authors concluded that
the coacervated (adsorbed) PY A molecules prevented the aggregation of PLGA
nanoparticles due to its steric hindrance (197).
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Following intravenous administration, the nanoparticles are taken up by
cells of the mononuclear phagocyte system mainly the Kupffer cells of the liver
and the spleen macrophages and are essentially lost (198, 199). This is considered
as the major hurdle to target delivery of drugs to other organ/tissue sites within
the body (198, 199). Several groups have tried to address this problem. Gref et
al. prepared polyethylene glycol (PEG)-coated nanospheres by employing a

amphiphilic diblock copolymer of PLGA (75:25, lactide:glycolide) and PEG
(molecular weight 5000-20,000) (198). The nanospheres were prepared by a
single-step o/w solvent evaporation technique, where the PEG fraction migrated
to the surface of the nanospheres forming a protective cover. After 5 minutes of
the injection of coated or uncoated nanospheres,

f 5% of coated nanospheres were

found in the liver and 60% of them in the blood with a significantly improved
circulating time (198). In comparison, 40% of uncoated nanospheres were found
in liver and only 15% of them in the blood. Also 4 hours post-injection, 30% of
coated nanospheres were still circulating in the blood while the plane nanospheres
had completely disappeared from the circulation. Blood circulation time for the
nanoparticles increased as the molecular weight of the PEG increased from 5000
to 20,000 due to increased thickness of the protective PEG layer which prevented
their opsonization (198). Stolnik et al. (199) and Dunn et al. (200) reported
preparation of PLGA nanospheres by o/w-emulsification/sol vent evaporation and
further coating them by the di block copolymer PLA:PEG (ratio of 2:5 and 3 :4).
The coated particles had increased hydrophilicity and decreased surface charge (as
determined by measuring their surface zeta potentials) and were sterically
stabilized particles. These particles exhibited reduced protein adsorption and Iiver
uptake and increased blood circulation time as compared to uncoated PLGA
nanospheres (199, 200). Leroux et al. have also reported similar improved site
specific drug delivery of nanoparticles after coating them with PEG ( 193). Other
groups have also reported successful preparation of PLGA nano particles (201204).

[III] OTHER DEVICES
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Many groups have reported preparation of drug-loaded implants from PLA
or PLGA (205-209). Kunou et al. have designed nail-like ganciclovir (GCV)
incorporated D,L-PLGA implant (length-5mm, diameter-I mm) for intraocular
drug delivery to treat cytomegalovirus retinitis (210). Wang et al. have reported
preparation (by compression) of 5-fluorouracil D,L-PLGA subconjunctival coated
and uncoated implants/matrices (5 mg, diameter-2.5mm, thickness-l .2mm) using
drug:PLGA ratio of9:1, 8:2, and 7:3 (211).
In order to study the release profile of zidovudine (AZT), Manda) et al.
prepared tablets by compressing physical mixture of AZT and PLGA (50:50) and
AZT loaded PLGA microcapsules (212). Other groups have also reported
preparation of PLA/PLGA compressed tablets with some involving use of heat
(213-215).
Schmitt et al. have reported preparation of amaranth incorporated pellets
(diameter-3.7 mm, thickness-3.1 mm) from D,L-PLGA which was purchased
from three different sources: DuPont, Birmingham Polymers, and Henley
Chemicals, Inc. (216). The authors prepared the pellets by melt-pressing spraydried PLGA with a 4-mm standard concave punch and die set (216). Tracy et al.
prepared drug-free PLGA pellets by a similar method but used a Carver
Laboratory Press instead (217).
In an article Schade et al. have described preparation of aqueous colloidal
D,L-PLGA dispersion by a spontaneous emulsification-solvent diffusion
technique followed by drying of these dispersions to form biodegradable latex
films (218). In order to study the effect of hydrophilic excipient on the drug
release from the hydrophobic PLGA (50:50) film, Song et al. prepared doublelayer films (150 µm thickness), where the drug releasing layer consisted of
drug/hydrophilic additive/PLGA (10:10:80 ratio) and a protecting layer consisting
of PLGA only (219). A combined solvent casting and melt-compression method
was utilized to prepare these films (219). In an effort to study drug-induced D,LPLA hydrolytic degradation, Li et al. prepared caffeine incorporated PLA circular
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plates (1.5 mm thick) and films (0.3 mm thin) (220). Other researchers have also
described drug delivery through PLGA films (221, 222).
Hsu et al. have reported preparation of low density PLGA (85: 15) foams,
having high interstitial void volume. First PLGA was dissolved in glacial acetic
acid at different concentrations (223, 224). The solutions were then frozen and
lyophilized and the solvent recovered in a dry ice/acetone cooled trap to give
foams which had leaflet or platelet structures. Lyophilization helped to achieve
control of the specific gravity and interstitial void volume of the foam. The drug
isoniazid (INH) was then impregnated into the foams, by immersing a weighed
quantity of foam into an aqueous INH solution of known concentration and finally
lyophilizing them to remove water. The foams" were then subjected to matrices
preparation by different methods using high pressure extrusion to prolong in vitro
release ofINH and to understand the mechanism of its release (223,224).

Lee et

al. have described preparation of biodegradable drug incorporated L-PLA porous

membranes (10 mg, 1 cm x 1 cm) for periodontal therapy by an in-air drying
phase inversion technique-which involved use of solvents like DCM and ethyl
acetate (225). Whang and Healy have described preparation of BSA incorporated
D, L-PLGA scaffolds having different pore sizes and very high porosities by an
emulsion freeze-drying method (226). Pore size was controlled by varying
polymer inherent viscosity and/or volume fraction of the dispersed aqueous phase
and/or polymer concentration (w/v %) (226). Ovalbumin loaded D,L-PLA
granules were prepared by first emulsification (o/w emulsion) of the vaccine
followed by lyophilization of the emulsion and then compression-molding the
powder into rods (227). These were then grounded by pestle and mortar into
granules which were then sized by using appropriate sieves (20 to I 00 ~Lm)(227,
228).

[IV] IN SITU FORMED IMPLANTS
The manufacturing processes for PLGA microparticles discussed in the
previous sections suffer from drawbacks such as: (i) the microspheres need to be
reconstituted (suspended) in an aqueous media, before they could be injected in
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the body, (ii) the hazards and environmental concern associated with the use of
organic solvents like methylene chloride for the solubilization of PLGA polymer,
and (iii) residual organic solvents remaining in the final microsphere product.
Although PLGA implants have been fabricated to deliver a variety of drug
classes, they have not received much commercial success, primarily due to
difficulty in administration; they require minor surgical incision or special type of
pellet injector (trocar), thereby causing inconvenience to the patients.
In order to improve patient acceptance a novel implant system has been
developed which is intramuscularly or subcutaneously administered as a liquid
and subsequently solidifies in situ (229, 230). First PLA or PLGA is dissolved by
heating in a water miscible, biocompatible solveri't (this may also act as a
plasticizer for the polymer). The polymer solution is then cooled under ambient
condition and the drug is dispersed into it by homogenization or alternatively, the
drug is dissolved in a solvent (like propylene glycol) which is miscible with the
polymer solvent and water. This polymer-solvent-drug system has a viscous
consistency but is sufficiently syringeable to be enabled to be injected
intramuscularly or subcutaneously by conventional syringe and needle. When
injected, it comes in contact with water from aqueous buffer (in vitro condition) or
physiological fluid (in vivo condition) and as a result the polymer precipitates and
forms a gel matrix (solidifies) entrapping the drug (in situ/in vitro or in situ/in
vivo implant formation). The polymer solvent dissipates and diffuses out of the
system and water diffuses into the polymer matrix. Due to water insoluble nature
of the polymer, it precipitates/coagulates to form a solid implant in situ, from
which the drug is released in a controlled fashion.
A number of groups including one at Atrix Laboratories have extensively
reported drug delivery using this method (229-246). These researchers have
employed combination of a host of biocompatible solvents and biodegradable
polyesters besides PLA and PLGA to deliver a variety of therapeutic drug classes
(229-246).
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Although this implant system precludes the need for any surgery for its
administration, it has a number of disadvantages: (i) the safety of solvents like
NMP used to formulate these systems is questionable and not well documented,
(ii) the injection of these liquid implant systems and their subsequent
solidification produce non-uniform matrix implants having variable consistency
and geometry, and (iii) due to formation of matrix implants having inconsistent
texture, shape and size, the drug release from them is variable and unpredictable.
An alternative and attractive approach therefore would be to use non-aqueous
solvents to produce in situ microspheres.

STERILIZATION OF PLGA BASED DEVICES
Sterilization of the final formulation containing the lactide and/or
glycolide polymers is an important issue often overlooked in the early stages of
drug delivery system development. Terminal sterilization and aseptic processing
are two main methods reported for sterilization of PLGA based products.
Steam sterilization usually involves subjecting the product to steam at 121°
C for at least 20 min or 115° C for 30 min (5, 12). This method cannot be used
with PLGA systems because at higher temperature/pressure condition the polymer
softens, melts and leads to deformation of the matrix form, and undergoes
hydrolysis (4 ). Heat sterilization involves exposing the product to higher
temperatures for longer periods of time which are destructive to both the polymer
and the entrapped drug (12). Sterilization using a gas like ethylene oxide can be
achieved when heat/steam sterilization are harmful to the formulation (4, 5, 12).
However ethylene oxide has known to soften and plasticize these polymers. Also
the residual gas vapors left in these device were found to be mutagenic,
carcinogenic, and allergic (4, 5).
Radiation sterilization (6 °Co y rays) has been used in several cases to
sterilize formulations containing lactide and/or glycolide polymers (4, 5, 12).
Effect ofradiation on PLGA has been a subject of various investigations (26, 53,
57, 59). Subjection of PLGA toy irradiation produced dose dependent polymer
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chain break down, molecular weight loss (decrease in inherent viscosity),
increased in vitro and in vivo bioerosion rates, and increased drug release kinetics
(59). Crossan and Whateley (53) and Spenlehauer et al. (247) have reported that
irradiation by y-rays did not in any way influence the drug release rates. In
another study, exposure of PLA to 100 Gy y-rays using
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Co did not affect the

microsphere structure, release rate, or the drug stability (26).
Aseptic processing is an effective but somewhat expensive technique for
formulations containing PLGA polymers (4, 5, 12). Due to excellent solubility of
these polymers in a number of organic solvents, they can be filter-sterilized. The
drug delivery system can then be formulated in a clean room environment using
Good Manufacturing Practice (GMP) protocols. ;

SUMMARY
Drug delivery from biodegradable PLGA polymers have generated
immense interest due to their excellent biocompatibility and biodegradability.
Also they are easy to formulate into drug carrying devices and have been
approved by the FDA for drug delivery use. The various biodegradable PLGA
devices fabricated from different techniques are versatile in terms of the various
classes of drugs encapsulated, the different time period of their release, and the
diverse routes of their delivery. PLGA microparticles, in particular, are important
drug delivery systems where various drug release profiles can be achieved by
adjusting the PLGA composition, molecular weight, drug loading, microparticle
size, porosity, and other factors. The newer techniques for fabricating PLGA
devices like the in situ formed implants are evidence of continued efforts by
researchers throughout the world to optimize the drug delivery through PLGA
polymer. Some drugs formulated into PLGA microparticles and other devices
have already been introduced into the market and many more are undergoing
clinical trials.

50

REFERENCES
(1) R. Jalil and J. R. Nixon, Journal of Microencapsulation, 7, 297-325, 1990.
(2) T. R. Tice and E. S. Tabibi in Treatise on Controlled Drug Delivery:
Fundamentals, Optimization, Applications (ed. A. Kydonieus), Marcel Dekl<:er,
Inc. (New York, NY), 315-339, 1991.
(3) X. S. Wu in Encyclopedic Handbook of Biomaterials and Bioengineering
(eds.: D. L. Wise et al.), Marcel Dekker, Inc. (New York, NY), 1015-1054, 1995.
(4) X. S. Wu in Encyclopedic Handbook of Biomaterials and Bioengineering
(eds.: D. L. Wise et al.), Marcel Dekker, Inc. (New York, NY), 1151-1200, 1995.
(5) D. H. Lewis in Biodegradable Polymers af Drug Delivery Systems (eds.: M.
Chasin and R. Langer), Marcel Dekker, Inc. (New York, NY), 1-41, 1990.
(6) J. Heller, Biomaterials, 1, 51-57, 1980.
(7) J. Heller, Critical Review of Therapeutic Drug Carrier System, 1, I, 39-90,

1984.
(8) J. Heller, Journal of Controlled Release, 2, 167-177, 1985.
(9) T. R. Tice and D.R. Cowsar, Pharmaceutical Technology, 11, 26-35, 1984.
(10) R. Arshady, Journal of Controlled Release, 17, 1-22, I 991.
(11) L. Brannon-Peppas, International Journal of Pharmaceutics, I I 6, 1-9, 1995.
(12) J.P. Kitchell and D. L. Wise, Methods in Enzymology, 112, 436-448, 1985.
(13) S. Cohen, M. J. Alonso, and R. Langer, International Journal of Technology
Assessment in Health Care, 10, 1, 121-130, 1994.
(14) M. Vert, Proceed. Intern. Conf. on Advances in Controlled Delivery
(Baltimore, MD), 32-36, 1996.
(15) Z. Zhao and K. W. Leong, Journal of Pharmaceutical Sciences, 85, 12, 12611270, 1996.
(16) J.E. Eldridge, J. K. Staas, D. Chen, P.A. Marx, T. R. Tice, and R. M. Gilley,
Seminars in Hematology, 30, 4, 16-24, 1993.

51

(17) T. Tice, R. Gilley, D. Mason, T. Ferrell, J. Staas, D. Love, A. McRae, A.
Dahlstrom, E. Ling, E. Jacob, and J. Setterstrom, Proceed. Intern. Conf. on
Advances in Controlled Delivery (Baltimore, MD), 30-31, 1996.
(18) D. M. Gilding, A. M. Reed, Polymer, 20, 1459-1464, 1979.
(19) K. Jamshidi, S. H. Hyon, and Y. Ikada, Polymer, 29, 2229-2234, 1988.
(20) C. Thies and M. C. Bissery, Biomedical Applications of Microencapsulation,
(ed., F. Lim), CRC Press, Boca Raton, FL, 53-74, 1984.
(21) R. S. Raghuvanshi, M. Singh, and G. P. Talwar, International Journal of
Pharmaceutics, 93, Rl-R5, 1993.
(22) J.M. Brady, D. E. Cutright, R. A. Miller, and G. C. Battistone, J. Biomed.
Mater. Res., 7, 155-166, 1973.
(23) J. W. Fong, Controlled Release Systems: Fabrication Technology, (ed., D.
Hsieh), vol. 1, CRC Press, Boca Raton, FL, 81-108, 1988.
(24) R. Wada, S.-H. Hyon, 0. Ike, S. Watanabe, Y. Shimizu, and Y. lkada,
Polym. Mater. Sci. Eng., 59, 803-806, 1988.
(25) M. Cavalier, J.P. Benoit, and C. Thies, Journal of Pharmacy and
Pharmacology, 38, 249-253, 1986.
(26) D. C. Tsai, S. A. Howard, T. F. Hogan, C. J. Malanga, S. J. Kandzari, and J.
K. H. Ma, Journal of Microencapsulation, 3, 3, 181-193, 1986.
(27) R. Bodmeier and J. W. McGinity, International Journal of Pharmaceutics, 43,
179-186, 1988.
(28) H. Sah, M. S. Smith, and R. T. Chern, Pharmaceutical Research, 13, 3, 360367, 1996.
(29) R. T. Chern, R. A. Wilson, J. Tang, and Z. Zhao, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 23, 363-364, 1996.
(30) H. Sah, M. S. Smith, and R. T. Chern, Proceed. Intern. Symp. Control. Rel.
Bioact. Mater., 22, 408-409, 1995.
(31) H. Yoshizawa, Y. Uemura, S. Natsugoe, K. Tokuda, M. Shimada, K.
Nakamura, T. Aikou, and Y. Hatate, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 23, 381-382, 1996.

52

(32) R.H. Reid, E. C. Boedeker, C. E. McQueen, D. Davis, L.-Y. Tseng, J.
Kodak, K. Sau, C. L. Wilhelmsen, R. Nellore, P. Dalal, and H. R. Bhagat,
Vaccine, 11, 2, 159-167, 1993.
(33) W. M. Vaughan, H. N. Duong, K. P. Blackman, B. A. Wood, J. A.
Setterstrom, and J.E. Van Hamont, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 23, 375-376, 1996.
(34) W. M. Vaughan, H. N. Duong, K. P. Blackman, B. A. Wood, J. A.
Setterstrom, and J.E. Van Hamont, Proceed. Intern. Conf. on Advances in
Controlled Delivery (Baltimore, MD), 43-44, 1996.
(35) S. J. Pak, H. N. Duong, K. P. Blackman, B. A. Wood, M. R. Lewis, V. R.
t'

Jimmerson, and J.E. Van Hamont, Proceed. Intern. Conf. on Advances in
Controlled Delivery (Baltimore, MD), 53-54, 1996.
(36) R. Jeyanthi, J. Van Hamont, K. Sau, F. Cassels, M. Wolf, R. Reid, and C.
McQueen, Proceed. Intern. Conf. on Advances in Controlled Delivery (Baltimore,
MD), 65-66, 1996.
(37) J. Van Hamont, E. Madden, R. Jeyanthi, G. Lara, R. Reid, and C. McQueen,
Proceed. Intern. Conf. on Advances in Controlled Delivery (Baltimore, MD), 7374, 1996.
(38) J. Van Hamont, R. Jeyanthi, K. Sau, F. Cassels, R. Reid, and C. McQueen,
Proceed. Intern. Conf. on Advances in Controlled Delivery (Baltimore, MD), 99100, 1996.
(39) E. Menagatti, E. Esposito, R. Cortesi, and C. Nastruzzi, Proceed. Intern.
Syrup. Control. Rel. Bioact. Mater., 22, 794-795, 1995.
(40) M. Kyo, S.-H. Hyon, and Y. lkada, Journal of Controlled Release, 35, 73-82,
1995.
(41) 0. Ike, S.-H. Hyon, S. Hitomi, H. Wada, Y. Ikada, and Y. Shimizu, Proceed.

Intern. Syrup. Control. Rel. Bioact. Mater., 23, 383-384, 1996.
(42) K. Itoi, C-Y. Tabata, 0. Ike, Y. Shimizu, M. Kuwabara, M. Kyo, S.-H. Hyon,
and Y. Ikada, Journal of Controlled Release, 42, 175-184, 1996.

53

(43) B. C. Thanoo, W. J. Doll, R. C. Mehta, G. A. Digenis, and P. P. DeLuca,
Pharmaceutical Research, 12, 12, 2060-2064, 1995.
(44) A.G. A. Coombes, P. D. Scholes, M. C. Davies, L. Illum, and S. S. Davis,
Biomaterials, 15, 9, 673-680, 1994.
(45) E. Polard, P. Le Corre, F. Chevanne, and R. Le Verge, International Journal
of Pharmaceutics, 134, 37-46, 1996.
(46) L. E. Beck, V. Z. Pope, C. E. Flowers, D.R. Cowsar, T. R. Tice, D. H.
Lewis, R. L. Dunn, A. B. Moore, and R. M. Gilley, Biology of Reproduction, 28,
186-195, 1983.
(47) D.R. Cowsar, T. R. Tice, R. M. Gilley, and J.P. English, Methods in
Enzymology, 112, 101-116, 1985.
(48) G. Spenlehauer, M. Veillard, and J.P. Benoit, Journal of Pharmaceutical
Sciences, 75, 750-755, 1986.
(49) P. Sansdrap and A. J. Moes, International Journal of Pharmaceutics, 98, 157164, 1993.
(50) J. H. Eldridge, J. K. Staas, J. A. Meulbroek, T. R. Tice, and R. M. Gilley,
Infection and Immunity, 59, 9, 2978-2986, 1991.
(51) V. Rosilio, J.P. Benoit, M. Deyme, C. Thies, and G. Madelmont, Journal of
Biomedical Materials Research, 25, 667-682, 1991.
(52) J.P. Benoit, T. Painbeni, and M. C. Venier-Julienne, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 23, 379-380, 1996.
(53) I. M. Crossan and T. L. Whateley, Proceed. Intern. Symp. Control. Rel.
Bioact. Mater., 21, 184-185, 1994.
(54) V. Joly, G. G. Encina, M. S. Cohen, and C. Thies, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 21, 282-283, 1994.
(55) C. Damge, M, Aprahamian, M. Koenig, A. Hoeltzel, G. Balboni, H.
Marchais, and J. P. Benoit, Proceed. Intern. Symp. Control. Rel. Bioact. Mater.,
21, 577-578, 1994.
(56) G. G. Giordano, M. F. Refojo, and M. H. Arroyo, Investigative
Ophthalmology & Visual Sciences, 34, 9, 2743-2751, 1993.

54

(57) Z. Zhou, M. Zhou, Z. Shen, and W. Shen, Biomat. Art. Cells & Immob.
Biotech., 21, 4, 475-486, 1993.
(58) A. Rolland, N. Wagner, A. Chatelus, B. Shroot, and H. Schaefer,
Pharmaceutical Research, 10, 12, 1738-1744, 1993.
(59) P. Menei, V. Daniel, C. Montero-Menei, M. Brouillard, A. PouplardBarthelaix, and J.P. Benoit, Biomaterials, 14, 6, 470-478, 1993.
(60) D. T. O'Hagan, D. Rahman, J.P. McGee, H. Jeffery, M. C. Davis, P.
Williams, S.S. Davis, and S. J. Challacombe, Immunology, 73, 239-242, 1991.
( 61) A. Delgado, C. Evora, and M. Llabres, International Journal of
Pharmaceutics,

140, 219-227, 1996.

(62) G. A. Brazeau, M. Sciame, S. A. Al-Suwa~~h, and E. Fattal, Pharmaceutical
Development and Technology, 1, 3, 279-283, 1996.
(63) K. Ciftci, A. A. Hincal, H. S. Kas, T. M. Ercan, A. Sungur, 0. Guven, and S.
Ruacan, Pharmaceutical Development and Technology, 2, 2, 151-160, 1997.
(64) J. F. Fitzgerald and 0. I. Corrigan, Journal of Controlled Release, 42, 125132, 1996.
(65) T. Richey and F. W. Harris, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 22, 416-417, 1995.
(66) S. Calis, R. Jeyanthi, T. Tsai, R. C. Mehta, and P. P. DeLuca, Pharmaceutical
Research, 12, 7, 1072-1076, 1995.
(67) V. A. Philip, R. C. Mehta, and P. P. DeLuca, International Journal of
Pharmaceutics,

151, 175-182, 1997.

(68) V. A. Philip, R. C. Mehta, M. K. Mazumdar, and P. P. DeLuca, International
Journal of Pharmaceutics,

151, 165-174, 1997.

(69) N. Wakiyama, K. Juni, and M. Nakano, Chemical and Pharmaceutical
Bulletin, 29, 3363-3368, 1981.
(70) J. W. Fong, H. V. Maulding, G. E. Visscher, J.P. Nazareno, and J.E.
Pearson, Controlled Release Technology, Pharmaceutical Applications (eds.: P.
Lee and W.R. Good), 214-231, 1987.
(71) R. Jalil and J. R. Nixon, Journal ofMicroencapsulation,

55

7, 25-39, 1990.

(72) L. Garcia-Contreras,

K. Abu-Izza, and D. R. Lu, Pharmaceutical

Development and Technology, 2, 1, 53-65, 1997.
(73) J.P. McGee, W. C. Koff, C. Y. Wang, B. Potts, R. C. Kennedy, and D. T.
O'Hagan, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 21, 871-872, 1994.
(74) R. Bodmeier and J. W. McGinity, Pharmaceutical Research, 4, 6, 465-471,
1987.
(75) S. S. Duggirala, R. C. Mehta, and P. P. DeLuca, Pharmaceutical
Development and Technology, 1, 1, 11-19, 1996.
(76) T. R. Tice and R. M. Gilley, Journal of Controlled Release, 2, 343-352, 1985.
(77) R. Jalil and J. R. Nixon, Journal of Microencapsulation,

7, 229-244, 1990.

(78) R. Bodmeier and J. W. McGinity, Journal tf Microencapsulation,

4, 279-288,

1987.
(79) M. J. Alonso, R. K. Gupta, C. Min, G. R. Siber, and R. Langer, Vaccine, 12,
4, 299-306, 1994.
(80) M. Singh, 0. Singh, and G. P. Talwar, Pharmaceutical Research, 12, 11,
1796-1800, 1995.
(81) S. Cohen, T. Yoshioka, M. Lucarelli, L. H. Hwang, and R. Langer,
Pharmaceutical Research, 8, 6, 713-720, 1991.
(82) B. R. Conway, H. 0. Alpar, and D. A. Lewis, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 21, 284-285, 1994.
(83) H. 0. Alpar, B. R. Conway, and J. C. Bowen, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 22, 564-565, 1995.
(84) Y. Ogawa, M. Yamamoto, H. Okada, T. Yashiki, and T. Shimamoto,
Chemical and Pharmaceutical Bulletin, 36, 3, 1095-1103, 1988.
(85) H. Okada, T. Heya, Y. Ogawa, and T. Shimamoto, The Journal of
Pharmacology and Experimental Therapeutics, 244, 2, 744-750, 1988.
(86) H. Toguchi, Clinical Therapeutics, 14, Suppl. A, 121-130, 1992.
(87) H. Okada, Y. Doken, Y. Ogawa, and H. Toguchi, Pharmaceutical Research,
11, 8, 1143-1147, 1994.

56

(88) A. Kamijo, S. Kamei, A. Saikawa, Y. Igari, and Y. Ogawa, Journal of
Controlled Release, 40, 269-276, 1996.
(89) H. Okada, Y. Daken, and Y. Ogawa, Journal of Pharmaceutical Sciences, 85,
10, 1044-1048, 1996.
(90) D. T. O'Hagen, H. Jeffery, M. J. J. Roberts, J.P. McGee, and S. S. Davis,
Vaccine, 9, 768-771, 1991.
(91) S. J. Challacombe, D. Rahman, H. Jeffery, S.S. Davis, and D. T. O'Hagan,
Immunology, 76, 164-168, 1992.
(92) H. Jeffery, S.S. Davis, and D. T. O'Hagan, Pharmaceutical Research, 10, 3,
362-368, 1993.
(93) D. T. O'Hagen, J.P. McGee, J. Holmgren~·A. M. Mowat, A. M. Donachie,
K. H. G. Mills, W. Gaisford, D. Rahman, and S. J. Challacombe, Vaccine, 11, 2,
149-153, 1993.
(94) D. T. O'Hagen, H. Jeffery, and S.S. Davis, Vaccine, 11, 9, 965-969, 1993.
(95) K. J. Maloy, A. M. Donachie, D. T. O'Hagen, and A. M. Mowat,
Immunology, 81, 661-667, 1994.
(96) S. Sharif, A. W. Wheeler, and D. T. O'Hagan, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 21, 294-295, 1994.
(97) S. Sharif, A. W. Wheeler, and D. T. O'Hagan, International Journal of
Pharmaceutics, 119, 239-246, 1995.
(98) D. T. O'Hagen, J.P. McGee, M. Lindblad, and J. Holmgren, International
Journal of Pharmaceutics, 119, 251-255, 1995.
(99) M. Singh, X.-M. Li, H. Qiu, T. Zamb, C. Y. Wang, and D. T. O'Hagan,
Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 367-368, 1996.
(100) M. J. Alonso, S. Cohen, T. G. Park, R. K. Gupta, G. R. Siber, and R.
Langer, Pharmaceutical Research, 10, 7, 945-953, 1993.
(101) G. L. Russell-Jones and H. Jeffery, Proceed. Intern. Symp. Control. Rel.
Bioact. Mater., 21, 873-874, 1994.
(102) M. Kende, C. Yan, W. Rill, R. Malli, R. Tammariello, and J. Hewetson,
Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 21, 875-876, 1994.

57

(103) J. L. Cleland, M. F. Powell, A. Lim, L. Barron, P. W. Berman, D. J.
Eastman, J. H. Nunberg, T. Wrin, and J. C. Vennari, AIDS Research and Hun1an
Retroviruses, 10, Suppl. 2, S21-S26, 1994.
(104) T. Uchida, S. Martin, T. Foster, R. C. Wardley, and S. Grimm,
Pharmaceutical Research, 11, 7, 1009-1015, 1994.
(105) T. Uchida and S. Goto, Biological and Pharmaceutical Bulletin, 17, 9, I 2721276, 1994.
(106) A.G. A. Coombes, E. C. Lavelle, P. G. Jenkins, and S.S. Davis, Proceed.
Intern. Symp. Control. Rel. Bioact. Mater., 22, 560-561, 1995.
(107) H. Sah, R. Toddywala, and Y. W. Chien, Journal of Controlled Release, 35,
l
137-144, 1995.
(108) R. S. Raghuvanshi, S. Ganga, A. Misra, S. Mehta, 0. Singh, and A. K.
Panda, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 859-860, 1996.
(109) A. Hilbert, T. Kissel, U. Fritzsche, M. Reers, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 23, 79-80, 1996.
(110) B. R. Conway, J.E. Eyles, and H. 0. Alpar, Proceed. Intern. Symp. Control.
Rel. Bioact. Mater., 23, 335-336, 1996.
(111) S. Ganga and 0. Singh, Proceed. Intern. Symp. Control. Rel. Bioact. Mater.,
23, 353-354, 1996.
(112) C. Sturesson, P. Artursson, L. Svensson, and J. Carlfors, Proceed. Intern.
Symp. Control. Rel. Bioact. Mater., 23, 515-516, 1996.
(113) J.M. Hilfinger, Y. Tsume, S. Beer, B. Davidson, J. R. Crison, and G. L.
Amidon, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 915-916, I 996.
(114) A.-C. Cheng and R. K. Gupta, Journal of Pharmaceutical Sciences, 85, 2,
129-132, 1996.
(115) G. Crotts, and T. G. Parks, Proceed. Intern. Conf. on Advances in
Controlled Delivery (Baltimore, MD), 75-76, 1996.
(116) H. Sah, R. Toddywala, and Y. W. Chien, Journal of Microencapsulation, I 2,
1, 59-69, 1995.

58

(117) H. Sah and Y. W. Chien, Journal of Pharmaceutical Sciences, 84, 11, 13531359, 1995.
(118) G. Crotts and T. G. Park, Journal of Controlled Release, 35, 91-105, 1995.
(119) H. Sah and Y. W. Chien, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 22, 776-777, 1995.
(120) H. Sah, R. Toddywala, and Y. W. Chien, Journal of Controlled Release, 30,
201-211, 1994.
(121) T. G. Park and G. Crotts, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 23, 355-356, 1996.
(122) S. Sharif and D. T. O'Hagan, International Journal of Phannaceutics, 115,

l

259-263, 1995.

(123) G. Reich, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22, 546-547,
1995.
(124) M.A. Benoit, B. Baras, B. B. C. Youan, G. Riveau, .I. Gillard, and A.
Capron, Proceed. Intern. Conf. on Advances in Controlled Delivery (Baltimore,
MD), 69-70, 1996.
(125) T. Heya, H. Okada, Y. Ogawa, and H. Toguchi, Journal of Pharmaceutical
Sciences, 83, 5, 636-640, 1994.
(126) T. Heya, Y. Mikura, A. Nagai, Y. Miura, T. Futo, Y. Tomida, H. Shimizu,
and H. Toguchi, Journal of Pharmaceutical Sciences, 83, 6, 798-801, 1994.
(127) J. L. Cleland, E.T. Duenas, J. Yang, H. Chu, V. Mukku, A. Mac, M.
Roussakis, D. Yeung, D. Brooks, Y.-F. Maa, C. Hsu, and A. J. S. Jones, Proceed.
Intern. Symp. Control. Rel. Bioact. Mater., 22, 149-150, 1995.
(128) J. L. Cleland and J. Yang, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 22, 518-519, 1995.
(129) W. Lu and T. G. Park, PDA Journal of Pharmaceutical Science and
Technology, 49, l, 13-19, 1995.
(130) M. J. Blanco-Prieto, E. Leo, F. Delie, A. Gulik, P. Couvreur, and E. Fattal,
Pharmaceutical Research, 13, 7, 1127-1129, 1996.

59

(131) T. Kissel, Y. X. Li, C. Volland, S. Gorich, and R. Koneberg, Journal of
Controlled Release, 39, 315-326, 1996.
(132) E. Esposito, R. Cortesi, F. Bortolotti, E. Manegatti, and C. Nastruzzi,
International Journal of Pharmaceutics, 129, 263-273, 1996.
(133) J. L. Cleland and A. J. S. Jones, Pharmaceutical Research, 13, 10, 14641475, 1996.
(134) J. L. Cleland, A. Mac, B. Boyd, J. Yang, E.T. Duenas, D. Yeung, D.
Brooks, C. Hsu, H. Chu, V. Mukku, and A. J. S. Jones, Pharmaceutical Research,
14,4,420-425,

1997.

(135) E.T. Duenas, J. Yang, A. J. S. Jones, and J. L. Cleland, Proceed. Intern.
Symp. Control. Rel. Bioact. Mater., 22, 516-51 , 1995.
(136) C. Yan, J. H. Resau, J. Hewetson, M. West, W. L. Rill, and M. Kende,
Journal of Controlled Release, 32, 231-241, 1994.
(13 7) I. Soriano, C. Evora, M. Llabres, International Journal of Pharmaceutics,
142, 135-142, 1996.
(138) M. J. Blanco-Prieto, E. Fattal, C. Durieux, B. P. Roques, and P. Couvreur,
Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 853-854, 1996.
(139) N. Erden and N. Celebi, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 21, 180-181, 1994.
(140) V. Labhasetwar, T. Underwood, M. Gallagher, G. Murphy, J. Langberg, and
R. J. Levy, Journal of Pharmaceutical Sciences, 83, 2, 156-164, 1994.
(141) C. Schugens, N. Laruelle, N. Nihant, C. Grandfils, R. Jerome and P.
Teyssie, Journal of Controlled Release, 32, 161-176, 1994.
(142) G. Crotts and T. G. Park, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 22, 81-82, 1995.
(143) T. K. Mandal, M. Shakleton, L. Washington, E. Onyebueke, and T. Penson,
Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22, 3305-3306, 1995.
(144) J. H. Kim, I. C. Kwon, Y. H. Kim, Y. T. Sohn, and S. Y. Jeong, Proceed.
Intern. Symp. Control. Rel. Bioact. Mater., 23, 341-342, 1996.

60

(145) J.E. Van Hamont, E. F. Madden, B. A. Wood, E. Jacob, and J. A.
Setterstrom, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 365-366,
1996.
(146) N. Erden and N. Celebi, International Journal of Pharmaceutics, 137, 57-66,
1996.
(147) T. K. Mandal and S. Tanjarla, International Journal of Pharmaceutics, 137,
187-197, 1996.
(148) R. Ghaderi, C. Sturesson, and J. Carlfors, International Journal of
Pharmaceutics, 141, 205-216, 1996.
(149) S. Akhtar and K. J. Lewis, International Journal of Pharmaceutics, 15 I, 5 7-

l

67, 1997.

(150) M. M. El-Baseir, M.A. Phipps, and I. W. Kellaway, International Journal of
Pharmaceutics, 151, 145-153, 1997.
(151) S. Takada, T. Kurokawa, K. Miyazaki, S. Iwasa, and Y. Ogawa,
International Journal of Pharmaceutics, 146, 147-15 7, 1997.
(152) N. Nihant, C. Grandfils, R. Jerome, and P. Teyssie, Journal of Controlled
Release, 35, 117-125, 1995.
(153) T. K. Mandal, M. Shakleton, K. B. Trinh, and T. N. Le, Proceed. Intern.
Symp. Control. Rel. Bioact. Mater., 22, 772-773, 1995.
(154) R. Edelman, R. G. Russell, G. Losonsky, B. D. Tall, C. 0. Tacket, M. M.
Levine, and D. H. Lewis, Vaccine, 11, 2, 155-158, 1993.
(155) V. J. Csernus, B. Szende, and A. V. Schally, International Journal of
Peptide and Protein Research, 35, 557-565, 1990.
(156) A. V. Schally and T. W. Redding, Proceed. Natl. Acad. Sci., 82, 2498-2502,
1985.
(157) L. M. Sanders, J. S. Kent, G. I. McRae, B. H. Vickery, T. R. Tice, and D. H.
Lewis, Journal of Pharmaceutical Sciences, 73, 9, 1294-1297, 1984.
(158) A.G. Hausberger, R. A. Kenley, and P. P. DeLuca, Pharmaceutical
Research, 12, 6, 851-856, 1995.

61

(159) N. Leelarasamee, S. A. Howard, C. J. Malanga, L.A. Luzzi, T. F. Hogan, S.
J. Kandzari, and J. K. H. Ma, Journal of Microencapsulation, 3, 171-179, 1986.

(160) C. Thomasin, H.P. Merkle, and B. A. Gander, International Journal of
Pharmaceutics, 147, 173-186, 1997.
(161) D. Pettit, S. Pankey, N. Nightlinger, M. Disis, and W. Gombotz, Proceed.
Intern. Symp. Control. Rel. Bioact. Mater., 23, 857-858, 1996.
(162) N. Nihant, S. Stassen, C. Grandfils, R. Jerome, P. Teyssie, and G. Goffinet,
Polym. Int., 34, 289-299, 1994.
(163) I. Esparza and T. Kissel, Vaccine, 10, 10, 714-720, 1992.
(164) J. W. Fong, U.S. Patent 4,166,800, 1997.
(165) J.M. Ruiz, B. Tissier, and J.P. Benoit, Intern~ional Journal of
Pharmaceutics, 49, 69-77, 1989.
(166) S. Takada, Y. Uda, H. Toguchi, and Y. Ogawa, PDA Journal of
Pharmaceutical Science and Technology, 49, 4, 180-184, 1995.
(167) B. W. Wagenaar and B. W. Mi.iller, Biomaterials, 15, 1, 49-54, 1994.
(168) D. L. Wise, G. J. McCormick, G. P. Willet, and L. C. Anderson, Life
Sciences, 19, 867-874, 1976.
(169) R. Bodmeier and J. W. McGinity, Journal of Microencapsulation, 5, 325330, 1988.
(170) H. Tamber, H.P. Merkle, M. W. Steward, C. D. Partidos, and B. Gander,
Proceed. Intern. Conf. on Advances in Controlled Delivery (Baltimore, MD), 129130, 1996.
(171) F. Castelli, B. Conti, U. Conte, and G. Puglisi, Journal of Controlled
Release, 40, 277-284, 1996.
(172) P.A. Dickinson, I. W. Kellaway, G. Taylor, D. Mohr, K. Nagels, and H.-M.
Wolff, International Journal of Pharmaceutics, 148, 55-61, 1997.
(173) Y. Men, G. Corradin, C. Thomasin, H.P. Merkle, and B. Gander, Proceed.
Intern. Symp. Control. Rel. Bioact. Mater., 21, 50-51, 1994.
(174) H.K. Lee, J. H. Park, and K. C. Kwon, Proceed. Intern. Symp. Control. Rel.
Bioact. Mater., 23, 333-334, 1996.

62

(175) K. Makino, M. Arakawa, and T. Kondo, Chemical and Pharmaceutical
Bulletin, 33, 3, 1195-1201, 1985.
(176) B. Wichert and P. Rohdewald, Journal of Controlled Release, 14, 269-283,
1990.
(177) M. Amin Khan, M. S. Healy, and H. Bernstein, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 19, 518-519, 1992.
(178) J. D. Herberger, C. Wu, N. Dong, and M.A. Tracy, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 23, 835-836, 1996.
(179) 0. L. Johnson, W. Jaworowicz, J. L. Cleland, L. Bailey, M. Charnis, E.
Duenas, C. Wu, D. Shepard, S. Magil, T. Last, A. J. S. Jones, and S. D. Putney,
Pharmaceutical Research, 14, 6, 730-735, 1997.

i

(180) A. P. Sam, F. de Haan, and C. Dirix, Proceed. Intern. Symp. Control. Rel.
Bioact. Mater., 21, 198-199, 1994.
(181) M. Iwata and J. W. McGinity, Journal ofMicroencapsulation,

9, 201-214,

1992.
(182) M. Iwata and J. W. McGinity, Pharmaceutical Research, 10, 8, 1219-1227,
1993.
(183) M. Madiba and X. S. Wu, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 23, 813-814, 1996.
(184) A. Sanchez, R. K. Gupta, M.A. Alonso, G. R. Siber, and R. Langer, Journal
of Pharmaceutical Sciences, 85, 6, 547-552, 1996.
(185) M. Hariharan and J. C. Price, Pharmaceutical Research, 13, 9, S-93, 1996.
(186) S. M. Abraham and D. J. Burgess, Pharmaceutical Research, 13, 9, S-219,
1996.
(187) P. J. Burns, T. R. Tice, D. Mason, D. Love, T. Ferrell, J. Gibson, K.
Dippert, and E. L. Squires, Proceed. Intern. Conf. on Advances in Controlled
Delivery (Baltimore, MD), 133-134, 1996.
(188) R. Bodmeier, H. Wang, D. J. Dixon, S. Mawson, and K. P. Johnston,
Pharmaceutical Research, 12, 8, 1211-1217, 1995.

63

(189) M.-K. Yeh, S.S. Davis, and A.G. A. Coombes, Pharmaceutical Research,
13, 11, 1693-1698, 1996.
(190) C. Song, V. Labhasetwar, L. Guzman, E. Topol, and R. J. Levy, Proceed.
Intern. Symp. Control. Rel. Bioact. Mater., 22, 444-445, 1995.
(191) G. F. Dawson and G. W. Halbert, Proceed. Intern. Symp. Control. Rel.
Bioact. Mater., 22, 424-425, 1995.
(192) R.H. Muller, S. Maa~en, H. Weyhers, F. Specht, and J. S. Lucks,
International Journal of Pharmaceutics, 138, 85-94, 1996.
(193) J.-C. Leroux, E. Allemann, F. De Jaeghere, E. Doelker, and R. Gurny,
Journal of Controlled Release, 39, 339-350, 1996.
(194) T. Niwa, H. Takeuchi, T. Hino, N. Kunou, and

. Kawashima, Journal of

Controlled Release, 25, 89-98, 1993.
(195) T. Niwa, H. Takeuchi, T. Hino, N. Kunou, and Y. Kawashima, Journal of
Pharmaceutical

Sciences, 83, 5, 727-732, 1994.

(196) T. Niwa, H. Takeuchi, T. Hino, M. Nohara, and Y. Kawashima,
International Journal of Pharmaceutics,

121, 45-54, 1995.

(197) H. Murakami, H. Yoshino, M. Mizobe, M. Kobayashi, H. Takeuchi, and Y.
Kawashima, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 361-362,
1996.
(198) R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and
R. Langer, Science, 263, 1600-1603, 1994.
(199) S. Stolnik, S. E. Dunn, M. C. Garnett, M. C. Davis, A.G. A. Coombes, D.
C. Taylor, M. P. Irving, S. C. Purkiss, T. F. Tadros, S. S. Davis, and L. Ilium,
Pharmaceutical Research, 11, 12, 1800-1808, 1994.
(200) S. E. Dunn, S. Stolnik, M. C. Garnett, M. C. Davis, A.G. A. Coombes, D.
C. Taylor, M. P. Irving, S. C. Purkiss, T. F. Tadros, S.S. Davis, and L. Ilium,
Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 21, 210-211, 1994.
(201) D. Quintanar-Guerrero,
Journal of Pharmaceutics,

H. Fessi, E. Allemann, and E. Doelker, International

143, 133-141, 1996.

64

(202) H. Murakami, Y. Kawashima, T. Niwa, T. Hino, H. Takeudii, and M.
Kobayashi, International Journal of Pharmaceutics, 149, 43-49, 1997.
(203) V. Labhasetwar, C. Song, W. Humphrey, R. Shebuski, and R. J. Levy,
Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22, 182-183, 1995.
(204) F. Nemati, C. Dubernet, H. Fessi, A. Colin de Verdiere, M. F. Poupon, F.
Puisieux, and P. Couvreur, International Journal of Pharmaceutics,

138, 237-246,

1996.
(205) L. M. Sanders, B. A. Kell, G. I. McRae, and G. W. Whitehead, Journal of
Pharmaceutical Sciences, 75, 4, 356-360, 1986.
(206) N. Heinrich, K. Fechner, H. Berger, D. Lorenz, E. Albrecht, G. Rafler, H.
1

Schafer, and B. Mehlis, Journal of Pharmacy and

harmacology, 43, 762- 765,

1991.
(207) A. C. Sharon and D. L. Wise, National Institue of Drug Abuse, 194-213,
1980.
(208) P.R. J. Gangadharam, S. Kailasam, S. Srinivasan, and D. L. Wise, The
British Journal for Antimicrobial Chemotherapy, 33, 265-271, 1994.
(209) S. Kailasam, D. L. Wise, and P.R. J. Gangadharam, The British Journal for
Antimicrobial Chemotherapy, 33, 273-279, 1994.
(210) N. Kunou, Y. Ogura, M. Hashizoe, Y. Honda, Y. Ikada, A. Ota, M. Hikida,
and Y. Kawashima, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 711712, 1996.
(211) G. Wang, I. G. Tucker, M. S. Roberts, and L. H. Hirst, Pharmaceutical
Research, 13, 7, 1059-1064, 1996.
(212) T. K. Manda!, A. Lopez-Anaya, and M. Shakleton, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 22, 770-771, 1995.
(213) M. Schellhorn and B. Buchholz, Proceed. Intern. Symp. Control. Rel.
Bioact. Mater., 23, 226-227, 1996.
(214) K. Mader, G. Bacic, A. Domb, and H. M. Swartz, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 22, 780-781, 1995.

65

(215) K. Mader, G. Bacic, A. Domb, R. Langer, and H. M. Swartz, Proceed.
Intern. Symp. Control. Rel. Bioact. Mater., 22, 77-78, 1995.
(216) E. A. Schmitt, D.R. Flanagan, and R. J. Linhardt, Journal of
Pharmaceutical Sciences, 82, 3, 326-329, 1993.
(217) M.A. Tracy, L. Firouzabadian, and Y. Zhang, Proceed. Intern. Syrnp.
Control. Rel. Bioact. Mater., 22, 786-787, 1995.
(218) A. Schade, T. Niwa, H. Takeuchi, T. Hino, and Y. Kawashima,
International Journal of Pharmaceutics, 117, 209-217, 1995.
(219) C. X. Song, V. Labhasetwar, and R. J. Levy, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 23, 473-474, 1996.
(220) S. Li, S. Girod-Holland, and M. Vert, Joufnal of Controlled Release, 40, 4153, 1996.
(221) B. Ronneberger, W. J. Kao, J. A. Anderson, and T. Kissel, Proceed. Intern.
Symp. Control. Rel. Bioact. Mater., 22, 778-779, 1995.
(222) Y. Zhang, S. Zale. L. Alukonis, and H. Bernstein, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 22, 83-84, 1995.
(223) Y.-Y. Hsu, J. D. Gresser, D. J. Trantolo, C. M. Lyons, P. R. J.
Gangadharam, and D. L. Wise, Journal of Controlled Release, 40, 293-302, 1996.
(224) Y.-Y. Hsu, J. D. Gresser, R.R. Stewart, D. J. Trantolo, C. M. Lyons, G. A.
Simons, P.R. J. Gangadharam, and D. L. Wise, Journal of Pharmaceutical
Sciences, 85, 7, 706-713, 1996.
(225) S. J. Lee, Y. J. Park, S. J. Ha, D. K. Kirn, J. L. Yeom, and C. P. Chung,
Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 23, 232-233, 1996.
(226) K. Whang and K. E. Healy, Proceed. Intern. Symp. Control. Rel. Bioact.
Mater., 22, 536-537, 1995.
(227) R. Nakaoke, Y. Tabata, and Y. lkada, Journal of Controlled Release, 40, 1121, 1996.
(228) S. S. Duggirala, J.B. Rodgers, and P. P. DeLuca, Pharmaceutical
Development and Technology, 1, 2, 165-174, 1996.

66

(229) N. H. Shah, A. S. Railkar, F. C. Chen, R. Tarantino, S. Kumar, M. Murjani,
D. Palmer, M. H. Infeld, and A. W. Malick, Journal of Controlled Release, 27.
139-147, 1993.
(230) M. L. Shively, B. A. Coonts, W. D. Renner, J. L. Southard, and A. T.
Bennett, Journal of Controlled Release, 33, 237-243, 1995.
(231) R. L. Dunn, A. J. Tipton, and E. M. Menardi, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 18, 465, 1991.
(232) R. L. Dunn, A. J. Tipton, G. L. Yewey, P. C. Reinhart, E. M. Menardi, .I. A.
Rogers, and G. L. Southard, American Association of Pharmaceutical Scientists,
Western Regional Meeting (Reno, NV), 189-191, 1992.
(233) S. M. Fujita, J.M. Sherman, K. C. GoAowski, A. J. Tipton, Pharmaceutical
Research, 9, 10, S-187, 1992.
(234) E.G. Duysen, G. L. Yewey, and R. L. Dunn, Pharmaceutical Research, 9,
10, S-73, 1992.
(235) A. J. Tipton, S. M. Fujita, K. R. Frank, and R. L. Dunn, Proceed. Intern.
Symp. Control. Rel. Bioact. Mater., 19, 314, 1992.
(236) B. K. Lowe, R. L. Norton, E. L. Keeler, K. R. Frank, and A . .I. Tipton, 19th
Annual Meeting of the Society for Biomaterials (Birmingham, AL), 1993.
(237) K. R. Frank, E.G. Duysen, G. L. Yewey, R. L. Dunn, W. E. Huffer, and R.
Pieters, Pharmaceutical Research, 11, 10, S-88, 1994.
(238) J. M. Sherman, S. M. Fujita, A. T. Bennett, J. L. Southard, S. L. Whitman,
R. L. Dunn, and G. L. Yewey, Pharmaceutical Research, 11, 10, S-318, 1994.
(239) E.G. Duysen, S. L. Whitman, N. L. Krinick, S. M. Fujita, and G. L. Yewey,
Pharmaceutical Research, 11, 10, S-88, 1994.
(240) S. M. G. Knight and R. L. Norton, 20th Annual Meeting of the Society for
Biomaterials (Boston, MA), 1994.
(241) R. L. Dunn, G. L. Yewey, E.G. Duysen, A. M. Polson, and G. L. Southard,
American Chemical Society Meeting (Washington D.C.), 1994.
(242) R. L. Dunn, G. L. Yewey, E.G. Duysen, K. R. Frank, W. E. Huffer, and R.
Pieters, Portland Bone Symposium, (Portland, OR), 1995.

67

(243) L.A. Moore, R. L. Norton, S. L. Whitman, and R. L. Dunn, 21st An11ual
Meeting of the Society for Biomaterials (San Francisco, CA), 1995.
(244) R. Dunn, G. Hardee, A. Polson, A. Bennett, S. Martin, R. Wardley, W.
Moseley, N. Krinick, T. Foster, K. Frank, and S. Cox, Proceed. Intern. Symp.
Control. Rel. Bioact. Mater., 22, 91-92, 1995.
(245) A. M. Polson, G. L. Southard, R. L. Dunn, A. P. Polson, J. R. Billen, and L.
L. Laster, The International Journal of Periodontics and Restorative Dentistry, 15,
1, 43-55, 1995.
(246) R. Eliaz and J. Kost, Proceed. Intern. Symp. Control. Rel. Bioact. Mater.,
23, 841-842, 1996.
(247) G. Spenlehauer, M. Vert, J.P. Benoit, F~~Chabot, and M. Veillard, Journal
of Controlled Release, 7, 217-229, 1988.

68

MANUSCRIPT II

CONTROLLED DELIVERY OF DRUGS FROM A NOVEL INJECTABLE IN

SITU FORMED BIODEGRADABLE PLGA MICROSPHERE SYSTEM
l

69

ABSTRACT
A novel method for in situ preparation of injectable biodegradable
microspheres from the copolymer poly(lactide-co-glycolide) (PLGA) without
incorporating unacceptable organic solvents is described. The delivery system is
a dispersion of PLGA microglobules ("premicrospheres" or "embryonic
microspheres") in an acceptable vehicle mixture (continuous phase) and whose
integrity is maintained by use of appropriate stabilizers. A solution of PLGA,
triacetin, a model protein (cytochrome c), PEG 400, and Tween 80 (Oil Phase 1)
are added dropwise with continuous homogenization to miglyol 812-Span 80
solution (Oil Phase 2), thereby inducing phase separation (coacervation) of PLGA
and forming PLGA microglobules (containing{ytochrome c) dispersed in the
continuous phase. This novel drug delivery system (NODS) is a dispersion and
has a viscous consistency, but is sufficiently syringeable. When injected, it comes
in contact with water from aqueous buffer or physiological fluid and as a result,
the microglobules harden to form solid matrix type microparticles entrapping
cytochrome c (in situ formed microspheres). Cytochrome c is then released from
these microspheres in a controlled fashion. The composition, rationale, and
optimization of the NODS is described here. Various formulation varibles such as
the PLGA concentration and type and the substitution of the continuous phase by
a fresh Oil Phase 2 influenced the characteristics of this sytem. The
characteristics of the NDDS were reproducible and were not affected by a 15
days/4° C storage condition. Also, the formulation, process, and storage (15
days/4° C) conditons did not adversely affect the physical stability of the
encapsulated cytochrome c.
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INTRODUCTION
The biodegradable thermoplastic aliphatic polyesters like poly(lactide)
(PLA), poly(glycolide) (PGA), and especially the copolymer of lactide and
glycolide referred to as poly(lactide-co-glycolide) (PLGA) have generated
immense interest due to their excellent biocompatibility and biodegradability [117]. Also PLGA has been approved by the FDA for a number of clinical
applications including surgical sutures and as controlled-release microspheres [3,
4]. PLGA is shown to be biocompatible and degrades to toxicologically
acceptable lactic and glycolic acids that are eventually eliminated from the body
[1].
There is a particular interest in controll{d delivery of macromolecules such
as peptides and proteins through PLGA microspheres [5]. Although a wide
variety of pharmacologically useful peptide and protein based drugs have been
recently developed by genetic engineering, their therapeutic use is restricted due
to certain disadvantages: [4, 5]: (I) on oral consumption they are subject to attack
by the acidic and enzymatic environment in the stomach and the enzymes from
the brush border membrane of the intestine, (2) their high molecular weight and
size impede their effective transport across the gastrointestinal membranes, and
(3) they have a short biological half-life and on injection they are quickly
metabolized and eliminated. To achieve sustained blood levels of these drugs,
prevent their denaturation or degradation, and to extend their biological half-life,
their delivery by encapsulation in PLGA microspheres has become an interesting
approach [4, 5].
The literature on PLGA microspheres is full of different techniques
describing their manufacture, where the microspheres are produced in a freeflowing, powder form. Some of the methods reported are [l, 2, 4, 5]: (1)
single/double emulsification followed by solvent removal by evaporation or
extraction, (2) phase separation (coacervation), and (3) spray-drying. Most of
these manufacturing processes suffer from drawbacks such as [ 1, 2, 4, 5]: ( 1) the
microspheres need to be reconstituted (suspended) in an aqueous media before
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their injection in the body, (2) the hazards and environmental concern associated
with the use of organic solvents like methylene chloride (dichloromethane)
(DCM) for the solubilization of PLGA polymer, and (3) residual organic solvents
remaining in the final microsphere product.
Shah et al. [18] and researchers from Atrix Laboratories, Inc. (Fort
Collins, CO) [19-26] have described a novel implant system which is parenterally
administered as a liquid and subsequently solidifies into a gel matrix (implant) in

situ, from which the drug is released in a controlled manner. Although this
implant system precludes the need for any surgery for its administration, it has a
number of disadvantages: (1) the safety of solvents like N-methyl-2-pyrrolidone
(NMP), used to formulate these systems is quetionable and not well documented,
(2) the injection of these liquid implant systems and their subsequent
solidification produce non-uniform matrix implants having variable consistency
and geometry, and (3) due to formation of matrix implants having inconsistent
texture, shape and size, the drug release from them is likely to be variable and
unpredictable.
In the present paper, a novel method of in situ preparation of PLGA
microspheres is described. The process of microsphere formation is based on the
principle of phase separation (coacervation). This method overcomes the
problems faced by the above systems by forming PLGA microglobules
("premicrospheres" or "embryonic microspheres") (Fig. 1). These microglobules
on coming in contact with water, harden to form discreet PLGA microspheres (in

situ formed microspheres) (Fig. 1). We describe here the composition, rationale,
and optimization of this NDDS using a model heme protein, cytochrome c. The
influence of various formulation variables such as the PLGA concentration and
type and the substitution of the continuous phase by a fresh Oil Phase 2, on the
characteristics of this sytem were evaluated. The reproducibility of the
characteristics of the NDDS were investigated. Also, the effect of the
formulation, process, and storage (15 days/4° C) conditions on the stability of the
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NDDS and the physical stability of the encapsulated cytochrome c were
determined.

MATERIALS
All the chemicals/reagents were used as purchased. Polyvinyl alcohol
(PV A) (87.0-89.0% partially hydrolyzed, molecular weight: 11,000-31,000) from
J. T. Baker (Phillipsburg, NJ), sodium azide and bovine heart cytochrome c
(molecular weight: 12,327) from Sigma Chemical Co. (St. Louis, MO); PLGA
RESOMER grades RG 502 Hand RO 503 H from Boehringer lngelheim
(Ingelheim, Germany); triacetin from Eastman Fine Chemicals (Rochester, NY);
polyethylene glycol 400 (PEG 400) from Uniolcarbide

Corporation (Danbury,

CT); miglyol 812 from Hills America, Inc. (Piscataway, NJ); Span 80 and Tween
80 from LC.I. (Wilmington, DE); DCM, n-hexane, and 2-propanol from Fisher
Scientific (Fair Lawn, NJ).

METHODS
Preparation of injectable PLGA microglobules and subsequent in situ
formation of microspheres
PLGA was dissolved in triacetin by magnetic stirring and heating to
approximately 65° C in a glass vial. The solution was cooled under ambient
condition and to it was added a solution of cytochrome c in PEG 400. This
mixture was magnetically stirred for 5 min followed by additon of Tween 80 and
further stirring for 5 min to form Oil Phase 1. Span 80 was dissolved in rniglyol
812 in a glass vial to form Oil Phase 2. Oil Phase I was added dropwise to Oil
Phase 2 with continuous homogenization at 10,000 rpm, using a Biohornogenizer
(Biospec Products Inc., Bartlesville, OK) for a period of 4 min, to form the NODS
[injectable dispersion of PLGA microglobules in a continuous phase consisting of
triacetin, PEG 400 and miglyol (and stabilized by Tween 80 and Span 80)]. The
same procedure was also repeated to produce blank PLGA microglobules.
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The ability of the NDDS to form microspheres in situ was performed in an
aqueous phosphate buffer. The NDDS in 1 ml quantity was injected in l O ml of
10 mM, 7.4 pH aqueous phosphate buffer contained in a 20 ml capacity glass vial.
The phosphate buffer also contained 0.02% w/v PVA as an anti-adherent and
0.02% w/v sodium azide as a preservative (bacteriostatic).

The above method was

also repeated to obtain blank in situ formed PLGA microspheres.
( 1) In vitro cytochrome c release
The glass vials containing the in situ formed microspheres were subjected
to agitation at 100 rpm at 3 7° C in a G24 Environmental Incubator Shaker from
New Brunswick Scientific Co., Inc. (Edison, NJ) (This step was also followed for
blank in situ formed PLGA microspheres).

satples

in l ml aliquot from each

vial were withdrawn at predetermined time intervals using a 0.5 ~Lmfilter
(Millipore Products Division, Bedford, MA) assisted 18G 1 needle/I cc plastic
syringe assembly (Beckton Dickinson & Co., Rutherford, NJ). The vials were
replenished with 1 ml of fresh aqueous phosphate buffer by passing it through the
same filter assisted needle/syringe assembly. The amount of cytochrome c
released from the in situ formed microspheres into the aqueous phosphate buffer
was quantitatively determined by its absorbance at 409 nm using a UV-Vis
Spectrophotometer from Varian (Varian Australia Pty. Ltd.). A standard
concentration curve was used to determine the concentration of cytochrome c in
the sample vials. The results were reported as mean of two experiments and for
each experiment the mean of three sample analysis were determined.
(2) pH change determination
The pH change due to erosion of the PLGA copolymer and subsequent
formation of lactic and glycolic acids was determined using a pH meter from
Orion Research, Inc. (Cambridge, MA) and an attached microelectrode from
Fisher Scientific. The vials containing the in situ formed microspheres were
subjected to agitation at 100 rpm at 37° C and the pH measured at predetermined
time intervals. The results were reported as mean of two experiments and for each
experiment the mean of three sample analysis were determined.
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(3) Optical microscopy
The transformation of the PLGA micro globules into in situ microspheres
was documented using an Aristomet light microscope (Leitz, Germany) attached
to a Kodak Megaplus camera. Samples representing different stages of
transformation were observed using color optics and the micrographs developed
using the Photoshot software from Adobe Systems, Inc. (San Jose, CA).

Extraction of the encapsulated cytochrome c from in situ formed PLGA
microspheres
The vials containing the in situ formed microspheres were transferred to
plastic centrifuging tubes, which were then centrifuged at 10,000 rpm for 10 min
using a Hermie Z382K centrifuging machine from benville Scientific, Inc.
(Metuchen, NJ). The PLGA microspheres were washed twice, each time with 5
ml ofn-hexane:2-propanol

(1:1). This was then followed by washing with 5 ml of

distilled water (twice). The tubes were then dried for 24 hr in a 282A lsotemp
vacuum oven from Fisher Scientific and the weight of the dried PLGA
microspheres determined. This was followed by addition of 5 ml of DCM to the
tubes to dissolve the PLGA copolymer and subsequent extraction of the
cytochrome c into 5 ml of distilled water. The aqueous phase containing the
recovered cytochrome c was then subjected to percentage encapsulation efficiency
study and circular dichroism (CD) spectroscopy.
The blank in situ formed PLGA microspheres were dried as above and
their weights evaluated at various predetermined time intervals.

( 1) Percentage cytochrome c encapsulation efficiency
The amount of cytochrome c in the aqueous phase was quantitatively
determined by its absorbace at 409 nm. The percentage encapsulation efficiency
was calculated by relating the practical cytochrome c entrapment to the
theroretical cytochrome c entrapment,
Practical cytochrome c entrapment(% w/w)/Theoretical cytochrome c entrapment
(% w/w) x 100
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The results were reported as mean of two experiments and for each experiment the
mean of three sample analysis were determined.
(2) CD spectroscopy
The physical stability of the encapsulated cytochrome c was investigated
by CD spectroscopy. The CD spectra were measured using a J- 710
spectropolarimeter from Jasco, Inc. (Easton, MD). The conditions of analysis
were as follows: pathlength, 0.1 cm (quartz cell); scan speed, 50 nm/min; step
resolution, 1 nm/data; sensitivity, 50 mdeg; band width, 1 nm; wavelength range,
190-250 nm (far UV). For each sample an average of two scans were recorded
using an attached SPL-430A X-Y plotter from Sekonic Company Ltd. (Japan).

;

(3) PLGA mass loss study

The blank in situ formed PLGA micro spheres were evaluated for mass
loss to study PLGA erosion by the gravimetry method. The percentage mass loss
was calculated using the equation,
M1 - M/M1

X

100

M 1= weight in grams of the in situ formed PLGA microspheres; M 2 = weight in
grams of the in situ formed PLGA microspheres at predetermined time intervals.
The results were reported as mean of two experiments and for each experiment the
mean of three sample analysis were determined.

Isolation of the in situ formed PLGA microspheres
The vials containing the in situ formed PLGA microspheres were
subjected to vacuum filtering using a 30 µm Whatman filter paper. This was
followed by washing and drying of the microspheres as above. The isolated
PLGA microsphere powder was then subjected to differential scanning
calorimetry (DSC), particle size determination, and scanning electron microscopy
(SEM) studies.

(1) DSC study
An SII differential scanning calorimeter from Seiko Instruments
(Horsham, PA) was used for the thermal analysis. All the samples in
approximately 3-7 mg quantity were weighed in standard aluminum pans which
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were then sealed. A pin-hole was made in the center of the caps to allow escape of
moisture during scanning. Thermograms were obtained at a scanning rate of 10°
C/min and a temperature range of 22 to 180° C. The heating chamber was
continuously purged with nitrogen gas at a rate of 50 ml/min. An attached 7550A
graphics plotter (Hewlett-Packard Company) recorded the DSC profiles of the
PLGA copolymer and the isolated in situ formed PLGA microspheres.
(2) Particle size determination study
The particle size of the isolated PLGA microspheres was determined using
a Master Sizer X from Malvern Instruments, Inc. (Southborough, MA). The
microspheres were first suspended in 100 ml of distilled water (containing J %
Tween 80) and subjected to sonication for 30 se{onds and vortex mixing for I 0
seconds before analysis. The volume average particle size of three scans for each
sample was reported.
(3) SEM study
The topological and morphological characteristics of the in situ formed
PLGA microspheres were documented by SEM. The isolated microspheres were
mounted on metal stubs with double sided tapes and sputter coated with gold for
90 sec at 15 mAmp. These were then viewed under a JEOL JSM-840A scanning
microscope (Peabody, MA) using 3 kV.

RESULTS AND DISCUSSION
Transformation of the PLGA microglobules into microspheres
Figure 2 depicts the optical micrographs of the different stages of
conversion of a PLGA microglobule into microsphere. The microglobule consists
of a rubbery PLGA matrix (Figure 2a). Figure 2b (8 min) illustrates an
incompletely formed PLGA microsphere. The vehicles associated with the
microglobules have been incompletely extracted in water, leading to formation of
an intermediate and transient stage between microglobule and microsphere.
Figure 2c (17 min) shows the final in situ formed PLGA microsphere. The
extraction of vehicles in water is complete, resulting into formation of a hard and
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opaque PLGA microsphere (containing cytochrome c). Due to the extraction of
the vehicles, the microglobule subsequently shrinks in size during its
transformation to the microsphere (Figure 2c ).

NDDS composition, rationale, and optimization:
Oil Phase 1
(1) PLGA copolymer
Different manufacturers supply various grades of PLGA copolymer that
are hydrophobic in nature and hence their hydrolytic degradion and subsequent
drug release is delayed [27-30). This delayed hydration of these polymers is due
to "capping" or "blocking" of the terminal carboxylic acid end groups by
esterification [27, 28). Recently Boehringer In{elheim has introduced new grades
of PLGA in which the carboxylic acid end groups are not esterified and are free,
thereby making these "uncapped" PLGA copolymers (RESOMER RG 50x H
grade) more hydrophilic (or less hydrophobic) than the contemporary "capped"
PLGA (RESOMER RG 50x grade) [27-30). There is not much difference
between RESOMER RG 50x and RESOMER RG 50x H grades with respect to
certain physico-chemical properties like molecular weight, inherent viscosity,
molar ratio, and glass transition temperature [30). However, RESOMER RG 50x
H grade being more hydrophilic, exhibits relatively rapid water uptake,
hydrolysis, and subsequent drug release with no 'lag time' as compared to the
RESOMER RG 50x grade [27-30).
Our goal was to achieve a rapid drug release from the final in situ formed
microspheres and hence we selected the "uncapped" PLGA copolymer grade.
The protein release was also dependent on the polymer molecular weight and its
composition, i.e. lactide:glycolide ratio [4]. PLGA copolymers having
lactide:glycolide ratio of 50:50 have been known to exhibit the fastest hydrolytic
degradation [3). Also for PLGA copolymer having similar composition, low
molecular weight polymers are more hydrophilic and thus more rapidly eroding
than the high molecular weight grades [3, 4). We therefore selected the
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"uncappped", low molecular weight, more hydrophilic RESOMER RG 502 H
grade for this invention.
The PLGA matrix should be strong enough to prevent leakage of the
micro globule content. It should also maintain the integrity and shape of the
microglobules and should not rupture or deform on redispersion of microglobules
back in the continuous phase on gentle agitation. PLGA was dissolved in triacetin
by heating to approximately 65° C. The concentraion of PLGA used was found to
be critical in this process and was optimized based on the PLGA/triacetin ratio
and was in the range of 0.05 to 0.22. Preliminary studies involving higher
PLGA/triacetin ratio(> 0.22) produced a sticky, coagulated PLGA mass (a nonmicroglobule product). In some cases, it even pr&luced PLGA solutions that
were too viscous to handle. Conversely, a low PLGA/triacetin ratio in these
studies(< 0.05) resulted in poor entrapment and rapid leakage of the microglobule
contents.

(2) Triacetin
Triacetin was selected to solubilize the PLGA polymer. Triacetin not only
acts as a solvent, but also as a plasticizer for the copolymer, as evident from the
DSC profiles in Fig. 3. The microencapsulation process resulted in a decrease in
the glass transition temperature (Tg) of the PLGA copolymer by 4° C (Fig. 3).
This decrease in Tg might affect the hydrolytic degradion (erosion) of the PLGA
matrix and the subsequent release of the drug from it [31]. The concentration of
triacetin plays an important role in this novel microencapsulation process and was
optimized based on the PLGA/triacetin ratio.

(3) PEG 400
PEG 400 was employed as the second vehicle in the formulation, and it
acted as a solvent for cytochrome c. The concentration of PEG 400 used in the
formulation was of great significance and was determined based on the
concentration of the PLGA-triacetin solution (i.e. PLGA-triacetin/PEG 400 ratio);
it was optimized in the range of 1.6 to 8.0. Initial studies involving absence or
very low PEG 400 concentrations (ratio> 8.0), produced a sticky and adhesive
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PLGA mass (a non-microglobule product). Also, higher concentrations of PEG
400 (ratio < 1.6) produced poor quality PLGA microglobules.
(4) Tween 80
When the non-aqueous dispersion comes in contact with water, Tween 80
(HLB = 15) facilitated the maintenance of the PLGA microglobule spherical
shape and also allowed efficient extraction of the vehicles in water. This resulted
in hardening of PLGA microglobules into discreet and deaggregated microspheres
which were then well dispersed in water. Experiments involving no Tween 80,
yielded PLGA microglobules which poorly dispersed on coming in contact with
water and they hardened into an agglomerated PLGA mass (a non-microsphere

t

product).
Oil Phase 2
(1) Miglyol 812

A fractionated coconut oil, miglyol 812 (C 8 :C 10 mixed triglycerides) was
incorporated as the third vehicle for this novel microencapsulation process and it
constituted the bulk of the continuous phase. The concentration of miglyol 812,
was determined based on the miglyol 812/Oil Phase 1 ratio and was optimized in
the range of 3.56 - 4.92. High concentration of miglyol 812 ensured complete
extraction of triacetin and much of PEG 400. Also, miglyol 812 builds up the
body of the dispersion and facilitates uniform redispersion of the PLGA
microglobules (settled at the base of the container) back in the continuous phase
on gentle agitation.
(2) Span 80
Span 80 (HLB = 4.3) prevented the PLGA microglobules from adhearing
to each other. Studies involving absence of Span 80 resulted in formation of a
sticky and agglomerated PLGA mass (a non-microglobule product).
Percentage cytochrome c encapsulation efficiency and particle size studies
As depicted in Figure 4, increasing the PLGA concentration increased the
percentage encapsulation efficiency of cytochrome c. The transportation of the
cytochrome c to the aqueous buffer during the hardening of the PLGA
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micro globules, leads to loss of cytochrome c. Extraction of the vehicles
associated with the microglobules eventually leads to their hardening into
microspheres, causing cessation of this transport. Increase in the PLGA
concentration of the Oil Phase 1, would result in faster hardening of the PLG A
micro globules. Also, higher viscosity of the Oil Phase 1 (due to higher PLGA
loading) would decrease the loss transport of cytochrome c and cause enhanced
percentage encapsulation efficiencies (Figure 4).
There was an increase in the microsphere size with increase in PLGA
concentration (Figure 4). A similar result has also been reported by other groups.
Higher PLGA concentration produces higher viscosity Oil Phase I, which leads to
a less effective coacervation process. As a r~sult, larger PLGA microglobules are
produced which subsequently get transformed to larger microspheres.

In vitro release of cytochrome c from the in situ formed PLGA microspheres
As shown in Figure 5, the in situ formed microspheres from the PLGA
microglobules exhibit a controlled release of cytochrome c. As reported by other
groups [4, 11, 13, 17], we suspect that the drug release from these rnicrospheres is
a combination of the following two mechanisms: diffusion through the
microsphere matrix and its hydrolytic degradation (which is controlled by factors
like PLGA molecular weight, crystallinity, and lactide:glycolide ratio). The
release of drug from these microspheres is associated with formation of pores and
they increase in number and size as the PLGA degradation proceeds, resulting in
subsequent faster release rates of the drug [4]. The burst effect (amount of
cytochrome c released by the end of day 1) is attributed mainly to the
unencapsulated cytochrome c.
(1) Effect of PLGA concentration
A strong burst effect was observed for the microspheres prepared with
lowest PLGA concentration (Figure 6). This is probably due to diffusion of
surface-localized cytochrome c and also due to high concentration of
unencapsulated cytochrome c, as a result of low percentage encapsulation
efficiency (Figure 4). The smaller size of these microspheres resulting in a higher
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surface area, as compared to the microspheres prepared using higher PLGA
concentrations, could also account for this effect. Depending upon the
PLGA/triacetin ratio, microglobules having different consistency are produced.
Microspheres from the lowest PLGA/triacetin ratio (0.05), have a less dense and
rigid PLGA matrix and hence they exhibit the fastest drug release. The opposite
is true for the microspheres prepared from the highest PLGA/triacetin ratio (0.18)
(Figure 6).
(2) Effect of PLGA type
The drug release profile of the in situ formed PLGA microspheres
prepared from RESOMER RG 502 H were compared with that of RG 503 I-I
(Figure 7). RG 503 H has a relatively higher mole~ular weight and is thus
relatively more hydrophobic than the RG 502 H grade. Hence RG 503 H
undergoes relatively slower hydrolytic degradation, thereby exhibiting relatively
lower burst and prolonged release of cytochrome c as compared to RG 502 I-I
(Figure 7).

(3) Effect ofreplacement of the continuous phase by a fresh Oil Phase 2
After the settling of the PLGA micro globules at the bottom of the glass
vial, the continuous phase consisting of triacetin, miglyol 812, and PEG 400 was
decanted and a fresh Oil Phase 2 was added to the PLGA microglobules. This
new NDDS was then compared to the original NODS with respect to cytochrome

c release profile (Figure 8). As expected, the in situ formed microspheres
produced from the new NODS exhibited relatively low burst and retarded
cytochrome c release as compared to those produced from the original NODS.
This could be due to absence of the unencapsulated cytochrome c in the fresh Oil
Phase 2.

PLGA erosion study

(1) pH change study
The difference in the PLGA erosion with respect to its loading was
determined by monitoring the pH changes, since random hydrolytic ester cleavage
produces polymer fragments with carboxylic acid end groups [32]. Figure 9a
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showes the pH change of the 10 mM, 7.4 pH aqueous phosphate buffer
(subsequent to in situ formation of PLGA microspheres) as the function of
incubation time. All the formulations showed a marked decrease in the pH of the
phosphate buffer with increasing incubation period. The hydrogen ions liberated
due to ionization of the carboxylic acid end groups of PLGA [32], overwhelm the
buffering capacity of the 10 ml, 10 mM phosphate buffer leading to a decrease in
its pH. The ionization process not only increases the permeability of the
microspheres, but also facilitates autocatalysis [32]. A series of these events are
responsible for the controlled release of cytochrome c from the in situ formed
microspheres. The use ofrelatively more hydrophilic, uncapped PLGA grade
1

(RESOMER RG 502 H) could be additionally res~ onsible for the observed
decrease in the pH. Microspheres prepared from the highest PLGA concentration
(ratio of 0.18) are relatively more hydrophobic than those prepared from the
lowest PLGA concentration (ratio of 0.05) and hence they exhibited the slowest
pH change of the phosphate buffer (Figure 9a).

(2) Mass loss study
The loss of mass of the in situ formed PLGA microspheres with increasing
incubation time also indicated the PLGA erosion of the in situ formed
microspheres (Figure 9b). This proved that they undergo extensive degradation to
produce water soluble monomers and oligomers, resulting in their weight loss
[32]. Highest PLGA concentration microspheres, since being more hydrophobic
showed the slowest degradation as compared to those prepared using the lowest
PLGA concentration (Figure 9b ).

Reproducibility of the characteristics of the NODS
In due course of time, the dispersed microglobules separate from the
continuous phase and tend to adhere and settle at the base of the container. It is
imperative that the NDDS exhibit no change in its characteristics on redispersion
by gentle agitation. Cytochrome c release profile of the in situ formed
microspheres produced from the original NDDS and a redispersed NDDS after 1
hr is shown in Figure 10. As shown, the release profile of cytochrome c was
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relatively unchanged. Also there was not much difference in the particle size and
the percentage encapuslation efficiency of the in situ formed microspheres
produced from the original and redispersed PLGA microglobules.

Stability studies of the NDDS
It is necessary for protein formulations to be stored at appropriate
conditions, inorder to maintain the stability of the encapsulated protein drug.
Hence the NDDS was stored at 4° C for a period of 15 days and the characteristics
of the system then evaluated after redispersion on gentle agitation. As depicted in
Figure 11, the release profiles of the in situ formed microspheres produced from
the original and stored PLGA microglobules are almost identical. Also there was
not much difference in their particle sizes and t{e percentage encapuslation
efficiencies This confirmed that the characteristics of the NDDS were unaltered
on their storage at 4° C for a period of 15 days.
It is of paramount importance to maintain the native protein conformation
and integrity during the encapsulation process. The physical stability of
cytochrome c was evaluated by CD spectroscopy. The CD profile of cytochrome
c in the far UV range provided the secondary structure of the protein. As evident

from Figures 12a and 12b the the ellipticity around 222 nm was not changed by
the formulation/process and the 15 days/4° C storage conditions respectively.
This suggested that the protein maintained its a-helical structure and thus its
physical stabilty.

SEM study of the in situ formed PLGA microspheres
Figures 13a and 13b reveals the topological and morphological
characterisics of the in situ formed PLGA microspheres as observed using SEM.
As shown, the microspheres are spherical and monodispersed in size (Figure 13a).
Also their surface shows very little or no pore structures (Figure 13b). Thus this
nov,el microencapsulation process tends to produce virtually non-porous
microspheres, unlike the solvent evaporation method which yields rnicrospheres
having porous surface structure. This could also explain the low burst effect
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observed for the microspheres in our study and the drug released by the end of
day one is the unencapsulated cytochrome c.

CONCLUSION
The composition, rationale, and optimization of the NODS is described
here. Various formulation varibles such as the PLGA concentration and type and
the substitution of the continuous phase by a fresh Oil Phase 2 influenced the
characteristics of this sytem. The NODS was reproducible and its characteristics
were not affected by the storage condition. The formulation, process, and storage
conditions did not affect the physical stability of the encapsulated cytochrome c.
The SEM study of these microspheres revealed

non-porous surface sturucture.

This novel microencapsulation process overcomes some of the disadvantages
associated with other methods by: ( 1) excluding the use of unacceptable organic
solvents like DCM or NMP and using acceptable vehicle mixture instead to
prepare biodegradable PLGA microspheres, (2) forming drug containing PLGA
microglobules ("premicrospheres" or "embryonic microspheres") which could be
considered as precursors to the final microsphere product; these on coming in
contact with water harden to form discreet PLGA microspheres which
subsequently exhibit non-variable, predictable, and controlled drug release profile,
and (3) precluding the need for reconstitution of the PLGA microspheres before
their administration. Thus, this novel microencapsulation method could be
viewed as a modified coacervation process, wherein cytochrome c containing
microglobules are converted to microspheres in situ. This process can also yield
microspheres in an isolated, powder form.
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Figure I-Schematic representation of the novel in situ PLGA microsphere
formation process
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Figure 2-Transformation of the PLGA microglobule into microsphere
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Figure 3-DSC profiles of the PLGA copolymer and the in situ formed PLGA
microsphere
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Figure 4-Effect of PLGA concentration on the particle size (µm) and percentage
cytochrome c encapsulation efficiency of the in situ formed microspheres (PLGA
concentration expressed as different ratios of PLGA/triacetin)
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Figure 5-In vitro release of cytochrome c from in situ formed PLGA microspheres
(PLGA concentration expressed as the ratio of PLGA/triacetin is 0.11)
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Figure 6-Controlled release of cytochrome c from in situ formed PLGA
microspheres prepared from NDDS containing different PLGA concentrations
(PLGA concentration expressed as different ratios of PLGA/triacetin)
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Figure 7-Controlled release of cytochrome c from in situ formed PLGA
microspheres prepared from NDDS containing different PLGA types
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Figure 8-Controlled release of cytochrome c from in situ formed PLGA
microspheres prepared from the original and modified NDDS (replacing the
continuous phase by fresh Oil Phase 2)
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Figure 9a-pH change of in situ formed PLGA microspheres prepared from NODS
containing different PLGA concentrations (PLGA concentration expressed as
different ratios of PLGA/triacetin)
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Figure 9b-Mass loss (erosion) of in situ formed PLGA microspheres prepared
from NDDS containing different PLGA concentrations (PLGA concentration
expressed as different ratios of PLGA/triacetin)
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Figure 10-Controlled release of cytochrome c from in situ formed PLGA
microspheres prepared from the original NDDS and the same NDDS on gentle
agitation after 1 hr (reproducibility of the characteristics of the NDDS)
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Figure I I-Controlled release of cytochrome c from in situ formed PLGA
microspheres prepared from the original NDDS and the same NDDS after storage
for 15 days at 4° C (stability study of the NDDS)
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Figure 12a-Effect of formulation and process conditions on the physical stability
of the encapsulated cytochrome c
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Figure 12b-Effect of 15 days/4° C storage condition on the physical stability of
the encapsulated cytochrome c
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Figure 13a-SEM picture of the in situ formed PLGA microspheres (low
magnification)
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Figure 13b-SEM picture of the in situ formed PLGA microspheres (high
magnification)
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MANUSCRIPT III

CONTROLLED RELEASE OF DRUGS FROM INJECTABLE IN SITU
FORMED BIODEGRADABLE PLGA MICROSPHERES: EFFECT
OF VARIOUS FORMULATION VARIABLES
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ABSTRACT
An in situ method for the preparation of injectable biodegradable
microspheres from the copolymer, poly(lactide-co-glycolide) (PLGA) for the
delivery of micromolecule and macromolecules such as proteins is described. The
delivery system is the same as described earlier (1) and it involves a stable
dispersion of PLGA microglobules ("premicrospheres" or "embryonic
microspheres") in an acceptable vehicle mixture (continuous phase). A solution of
PLGA, triacetin, drug, PEG 400, and Tween 80 (Oil Phase I) are added dropwise
with continuous homogenization to miglyol 812-Span 80 solution (Oil Phase 2),
thereby inducing phase separation (coacervation) of PLGA and forming PLGA
microglobules (containing the drug) dispersed in the Continuous phase. This
novel drug delivery system (NDDS) on injection comes in contact with water
from aqueous buffer or physiological fluid, thereby hardening the microglobules
into solid matrix type microparticles entrapping the drug (in situ formed
microspheres) (1). The drug is then released from these microspheres in a
controlled fashion. The concentration of PEG 400, the encapsulated drug, and the
added hydrophilic excipient (mannitol) affected the characteristics of this NODS.
The characteristics were also influenced by the types of encapsulated drug and the
vehicles added to the system. The physcial stability of the encapsulated protein
was unaffected by the formulation, process, and the 15 days/4° C storage
conditions.
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INTRODUCTION
There is a particular interest in controlled delivery of macromolecules such
as peptides and proteins through PLGA (the copolymer of lactic and glycolic
acids) microspheres and a wealth ofliterature has been generated on this issue (218). PLGAs have shown to be biocompatible and they degrade to toxicologically
acceptable lactic and glycolic acids that are eventually eliminated from the body
(2). Also, they have been approved by the FDA as controlled drug release
microspheres (4, 5).
The NDDS is the same as described earlier (1) (Figure 1) and it involves a
stable dispersion of PLGA microglobules ("premicrospheres" or "embryonic
microspheres") in a continuous phase consisting

J acceptable vehicle mixture.

This on injection, comes in contact with water from aqueous buffer or
physiological fluid, thereby hardening the microglobules into solid matrix type
microparticles entrapping the drug (in situ formed microspheres) (1 ). The drug is
then released from these microspheres in a controlled fashion. This novel process
overcomes some of the disadvantages associated with other methods by: (i)
replacing the unacceptable organic solvents by an acceptable vehicle mixture to
prepare biodegradable PLGA microspheres, (ii) producing drug containing PLGA
microglobules ("premicrospheres" or "embryonic microspheres") which could be
considered as precursors to the final microsphere product; these on coming in
contact with water harden to form discreet PLGA microspheres which
subsequently exhibit non-variable, predictable, and controlled drug release profile,
and (iii) avoiding the need for reconstitution of the PLGA microspheres before
their administration ( 1).
In our previous study we had described the composition, rationale, and
optimization of the NDDS (I). Various formulation variables such as the PLGA
loading and type and the substitution of the continuous phase by a fresh Oil Phase
2 influenced the characteristics of this system. The NDDS was reproducible and
its characteristics were not affected by the storage condition (1). Circular
dichroism (CD) spectroscopy revealed that the formulation, process, and the
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storage conditions did not adversely affect the physical stability of the
encapsulated protein, cytochrome c. The scanning electron microscopy study of
these microspheres revealed spherical and monodispersed particles having nonporous surface structures ( 1).
In this study, we have investigated the effect of the following formulation
variables on the characteristics of the NDDS: (i) the concentrations of PEG 400,
the encapsulated drug, and the hydrophilic excipient (mannitol) and (ii) the types
of encapsulated drug and the vehicles. Also, the effect of formulation, process,
and storage (15 days/4° C) conditions on the stability of the encapsulated protein
was evaluated.

MATERIALS
All the chemicals/reagents were used as purchased. Polyvinyl alcohol
(PV A) (87.0-89.0% partially hydrolyzed, molecular weight: 11,000-31,000) from
J. T. Baker (Phillipsburg, NJ); sodium azide, bovine heart cytochrome c
(molecular weight: 12, 327), and heart skeletal muscle myoglobin (molecular
weight: 16, 950) from Sigma Chemical Co. (St. Louis, MO); red D&C #33 dye
(red dye) from Pylam Products Corp. (Garden City, NY); PLGA RESOMER
grade RG 502 H from Boehringer Ingelheim (Ingelheim, Germany); triacetin from
Eastman Fine Chemicals (Rochester, NY); triethyl citrate from Morflex Chemical
Co. (Greensboro, NC); polyethylene glycol 400 (PEG 400) from Union Carbide
Corp. (Danbury, CT); miglyol 812 from Hills America, Inc. (Piscataway, NJ);
soybean oil from Welch, Holme & Clark Co., Inc. (Newark, NJ); mannitol from
Roquette America, Inc. (Keokuk, IA); Span 80 and Tween 80 from I.C.I.
(Wilmington, DE); methylene chloride, n-hexane, and 2-propanol from Fisher
Scientific (Fair Lawn, NJ).

METHODS
NDDS formation
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PLGA was dissolved in triacetin by magnetic stirring and heating to
approximately 65° C in a glass vial. The solution was cooled under ambient
condition and to it was added a solution of cytochrome c in PEG 400. This
mixture was magnetically stirred for 5 min followed by additon of Tween 80 and
further stirring for 5 min to form Oil Phase 1. Span 80 was dissolved in miglyol
812 in a glass vial to form Oil Phase 2. Oil Phase 1 was added dropwise to Oil
Phase 2 with continuous homogenization at 10,000 rpm, using a Biohomogenizer
(Biospec Products Inc., Bartlesville, OK) for a period of 4 min, to form the NDDS
[injectable dispersion of PLGA microglobules in a continuous phase consisting of
triacetin, PEG 400 and miglyol (and stabilized by Tween 80 and Span 80)].

I
Optical microscopy
The transformation of the PLGA microglobules into in situ microspheres
was documented using an Aristomet light microscope (Leitz, Germany) attached
to a Kodak Megaplus camera. Samples representing different stages of the
transformation were observed using color optics and the micrographs developed
using the Photoshot software from Adobe Systems, Inc. (San Jose, CA).

In vitro drug release from the in situ formed PLGA microspheres
The NDDS in 1 ml quantity was injected in 10 ml of 10 mM, 7.4 pH
aqueous phosphate buffer contained in a 20 ml capacity glass vial to in situ form
microspheres.

The phosphate buffer also contained 0.02% w/v PV A as an anti-

adherent and 0.02% w/v sodium azide as a preservative (bacteriostatic).

The glass

vials containing the in situ formed microspheres were subjected to agitation at I 00
rpm at 37° Cina

G24 Environmental Incubator Shaker from New Brunswick

Scientific Co., Inc. (Edison, NJ). Samples in 1 ml aliquot from each vial were
withdrawn at predetermined time intervals using a 0.5 µm filter (Millipore
Products Division, Bedford, MA) assisted 18G 1 needle/I cc plastic syringe
assembly (Beckton Dickinson & Co., Rutherford, NJ). The vials were replenished
with 1 ml of fresh aqueous phosphate buffer by passing it through the same filter

110

assisted needle/syringe assembly. The amount of drug released from the in situ
formed microspheres into the aqueous phosphate buffer was quantitatively
determined using a UV-Vis Spectrophotometer from Varian (Varian Australia
Pty. Ltd.). The wave length used for the analysis of the red dye was 530 nm while
the proteins, cytochrome c and myoglobin were analyzed at 409 nm. A standard
concentration curve was used to determine the concentration of the drug in the
sample vials. The results were reported as mean of two experiments and for each
experiment the mean of three sample analysis were determined.

Percentage encapsulation efficiency and CD spectroscopy studies
The vials containing the in situ formed mic/ospheres were transferred to
plastic centrifuging tubes, which were then centrifuged at 10, 000 rpm for IO min
using a Hermie Z382K centrifuging machine from Denville Scientific, Inc.
(Metuchen, NJ). The PLGA microspheres were washed twice, each time with 5
ml ofn-hexane:2-propanol (1:1). This was then followed by washing with 5 ml of
distilled water (twice). The tubes were then dried for 24 hr in a 282A Isotemp
vacuum oven from Fisher Scientific and the weight of the dried PLGA
microspheres determined. This was followed by addition of 5 ml of methylene
chloride to the tubes to dissolve the PLGA copolymer and subsequent extraction
of the cytochrome c into 5 ml of distilled water. This process was also repeated
for myoglobin-encapsulated microspheres.
The amount of cytochrome c in the aqueous phase was quantitatively
determined by its absorbance at 409 nm. The percentage encapsulation efficiency
was calculated by relating the practical cytochrome c entrapment to the theoretical
cytochrome c entrapment,
Practical cytochrome c entrapment(% w/w)/Theoretical cytochrome c entrapment
(% w/w) x 100
The results were reported as mean of two experiments and for each experiment the
mean of three sample analysis were determined.
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The aqueous phase containing the extracted myoglobin was subjected to
CD spectroscopy using a J- 710 spectropolarimeter from Jasco, Inc. (Easton, MD).
The conditions of analysis were as follows: pathlength, 0.1 cm (quartz cell); scan
speed, 50 nm/min; step resolution, 1 nm/data; sensitivity, 50 mdeg; band width, 1
nm; wavelength range, 190-250 nm (far UV). For each sample an average of two
scans were recorded using an attached SPL-430A X-Y plotter from Sekonic
Company Ltd. (Japan).

RESULTS AND DISCUSSION

In situ formation of PLGA microspheres
In our previous paper, we had shown by opfical microscopy the process of
transformation of the PLGA microglobules into microspheres ( 1). This
transformation occurred in approximately 17 min ( 1). Figure 2a shows the
rubbery PLGA microglobules (containing the red dye) while Figure 2b shows the
hard and opaque in situ formed microspheres (17 min after injection of the
microglobules in the aqueous phosphate buffer). The microglobules on coming in
contact with water harden to form solid matrix type microparticles entrapping the
drug (in situ formed microspheres) (1 ). Also, due to the extraction of the vehicles
associated with the microglobules by water, they subsequently shrink in size
during their transformation to microspheres (Figures 2a and 26) (1).

In vitro release of drugs from the in situ formed PLGA microspheres
As discussed in our previous paper, the in situ formed microspheres from
the PLGA microglobules exhibited a controlled cytochrome c release from few
days upto two weeks, depending upon various formulation variables (1 ). The
burst effect (amount of cytochrome c released by the end of day 1) was mainly
due to the unencapsulated cytochrome c ( 1).
( 1) Effect of encapsulating different drug type
Proteins are too large to diffuse through the polymer matrix and their
release occurs via diffusion through the interconnecting channels and pores
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formed by them in the matrix (5, 19). The proteins are also released by the
hydrolytic degradation (erosion) of the matrix (5, 19). Kissel et al. have reported
a decrease in the release of the encapsulated proteins with increase in their
molecular weights (20). Figure 3 shows the in vitro drug release profile of the red
dye, cytochrome c and myoglobin from the in situ formed PLGA microspheres.
As shown, the release of myoglobin (molecular weight: 16, 950) is slightly
slower than cytochrome c (molecular weight: 12, 327). Also, the red dye (a
micromolecule) is released rapidly from the PLGA matrix due to its faster
diffusion from the matrix (Figure 3).
(2) Effect of PEG 400 and drug loading
The concentration of PEG 400 used in thf formulation was of great
significance and was determined based on the concentration of the PLGA-triacetin
solution (i.e. PLGA-triacetin/PEG 400 ratio). The PEG 400 concentration was
optimized in the range of 1.59 to 7.97 (1 ). Decrease in the concentration of PEG
400 (ratio of 6.03) produces a concentrated PEG 400-cytochrome c solution.
Thus more drug is available to be encapsulated by the PLGA microglobules,
resulting in higher percentage cytochrome c encapsulation efficiency (Figure 4a).
This increased concentration of the encapsulated cytochrome c results in an
increase in the interconnecting channels and pores in the PLGA matrix, leading to
higher release rate and faster drug release profile (Figure 4a). An increase in the
concentration of cytochrome c also produces a concentrated PEG 400-cytochrome
c solution. Thus more drug is encapsulated by the PLGA microglobules, resulting
in higher percentage cytochrome c encapsulation efficiencies and accelerated
release profile (Figure 4b ).
(3) Effect of addition of an hydrophilic excipient (mannitol)
Figure 5 shows the release of myoglobin in presence of the hydrophilic
excipeint, mannitol. Various groups have reported the effect of different
additives/excipients on the drug release from the PLGA microparticles (5, 19, 21 ).
Proteins are released from the PLGA matrix by diffusion from the interconnecting
channels and pores formed by them in the matrix and by the hydrolytic
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degradation (erosion) of the matrix. Addition of co-diffusants like mannitol
imparts porosity to the PLGA matrix, thereby changing the matrix structure and
providing increased diffusion through interconnecting channels for the release of
the proteins. Thus, increase in the concentration of mannitol leads to subsequent
higher protein release profile due to formation of highly porous PLGA matrix
(Figure 5). We suspect that an increase in the mannitol concentration would lead to
subsequent lower percentage encapsulation efficiencies, as mannitol would
compete with myoglobin to be encapsulated by the PLGA microglobules.
(4) Effect of using different vehicles
The plasticizer, triacetin (solubility in water: 77.8 mg/ml) is relatively
more hydrophilic than triethyl citrate (solubility1n water: 55.4 mg/ml) (22). Thus
triethyl citrate would cause relatively greater plasticization of the hydrophobic
PLGA copolymer than triacetin. Hence microspheres prepared using triethyl
citrate would undergo relatively enhanced hydrolytic degradation and subsequent
faster release of the drug as compared to those formulated using triacetin (Figure
6a).
Soybean oil (mixed triglyceride of unsaturated and saturated fatty acids) is
relatively more hydrophobic than miglyol 812 (mixed C 8-C 10 triglyceride of
saturated fatty acids). Hence use of soybean oil produces relatively more
hydrophobic PLGA microglobule dispersion than those formulated using miglyol
812, thereby delaying the dissolution of the released myoglobin. Thus
microspheres prepared from NDDS containing soybean oil exhibit relatively
retarded myoglobin release as compared to those produced from NDDS
containing miglyol 812 (Figure 6b ).

Stability of the encapsulated myoglobin

It is important to maintain the native protein conformation and its stability
during the encapsulation process. In our previous paper, we had shown by CD
spectroscopy that the formulation, process and the 15 days/4° C storage conditions
did not adversely affect the physical stability of the encapsulated cytochrome c
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(1). The CD profile of myoglobin in the far UV range (which provided the

secondary structure of the protein) has been shown in Figures 7a and 7b. As
evident from these figures, the ellipticity around 222 nm was unaffected by the
formulation/process and the 15 days/4° C storage conditions. This suggested that
the protein maintained its a-helical structure and hence its physical stability.

CONCLUSION
Controlled release of micromolecule and proteins from the in situ formed
PLGA microspheres produced from a novel coacervation process is described
here. The in vitro drug release was enhanced with decrease in the PEG 400
concentration and increase in the drug and mannitof concentration. The drug
release was retarded with increase in the molecular weight of the encapsulated
drug. Substitution of triacetin by triethyl citrate accelerated the drug release while
replacing miglyol 812 with soybean oil slowed the drug release from the in situ
formed microspheres. The stability of the encapsulated myoglobin was
unaffected by the formulation, process, and the storage conditions. This novel
microencapsulation process, besides producing microspheres in situ, also yielded
microspheres in an isolated, powder form.

ACKNOWLEDGEMENTS
The authors greatly appreciate the financial support and the research
facilities provided for this project by Hoffmann-La Roche Inc. (Nutley, NJ).

REFERENCES
1.

R. Jain, N. H. Shah, A. S. Railkar, A. W. Malick, and C. T. Rhodes.

Journal of Controlled Release (submitted for publication).

2.

R. Jalil and J. R. Nixon. Biodegradable poly(lactic acid) and poly(lactideco-glycolide) microcapsules: Problems associated with preparative
techniques and release properties. Journal o/Microencapsulation.
325 (1990).

115

7: 297-

3.

T. R. Tice and E. S. Tabibi. Parenteral drug delivery: injectables. In: A.
Kydonieus (ed.),Treatise on Controlled Drug Delivery: Fundamentals,

Optimization, Applications, Marcel Dekker, Inc. (New York, NY), 199 I,
pp. 315-339.
4.

X. S. Wu. Synthesis and properties of biodegradable lactic/glycolic acid
polymers. In: D. L. Wise et al. (eds.), Encyclopedic Handbook of

Biomaterials and Bioengineering, Marcel Dekker, Inc. (New York, NY),
1995, pp. 1015-1054.
5.

X. S. Wu. Preparation, characterization, and drug delivery applications of
microspheres based on biodegradable lactic/glycolic acid polymers. In: D.
;)_

L. Wise et al. (eds.), Encyclopedic Handbook of Biomaterials and

Bioengineering, Marcel Dekker, Inc. (New York, NY), 1995, pp. 11511200.
6.

D. H. Lewis. Controlled release of bioactive agents from lactide/glycolide
polymers. In: M. Chasin and R. Langer (eds.), Biodegradable Polymers as

Drug Delivery Systems, Marcel Dekker, Inc. (New York, NY), 1990, pp.
1-41.
7.

J. Heller. Controlled release of biologically active compounds from
bioerodible polymers. Biomaterials. 1: 51-57 ( 1980).

8.

J. Heller. Biodegradable polymers in controlled drug delivery. Critical

Review of Therapeutic Drug Carrier System. 1, 1: 39-90 (1984).
9.

J. Heller. Controlled drug release from poly(ortho esters)-a surface eroding
polymer. Journal of Controlled Release. 2: 167-177 (1985).

10.

T. R. Tice and D. R. Cowsar. Biodegradable controlled-release parenteral
systems. Pharmaceutical Technology. 11: 26-35 (1984).

11.

R. Arshady. Preparation of biodegradable microspheres and
microcapsules: 2. Polylactides and related polyesters . .Journal ol

Controlled Release. 17: 1-22 (1991 ).

116

12.

L. Brannon-Peppas. Recent advances on the use of biodegradable
microparticles and nanoparticles in controlled drug delivery. International

Journal of Pharmaceutics. 116: 1-9 (1995).
13.

J.P. Kitchell and D. L. Wise. Poly(lactic/glycolic

acid) biodegradable

drug-polymer matrix systems. Methods in Enzymology. 112: 436-448
(1985).
14.

S. Cohen, M. J. Alonso, and R. Langer. Novel approaches to controlledrelease antigen delivery. International Journal of Technology Assessment

in Health Care. 10, 1: 121-130 (1994).
15.

M. Vert. The complexity of PLAGA-based drug delivery systems.

Proceed. Intern. Conj. on Advances in ~ntrolled

Delivery (Baltimore,

MD) 32-36 (1996).
16.

Z. Zhao and K. W. Leong. Controlled delivery of antigens and adjuvants
in vaccine development. Journal of Pharmaceutical Sciences. 85, 12:
1261-1270 (1996).

17.

J.E. Eldridge, J. K. Staas, D. Chen, P.A. Marx, T. R. Tice, and R. M.
Gilley. New advances in vaccine delivery systems. Seminars in

Hematology. 30, 4: 16-24 (1993).
18.

T. Tice, R. Gilley, D. Mason, T. Ferrell, J. Staas, D. Love, A. McRae, A.
Dahlstrom, E. Ling, E. Jacob, and J. Setterstrom. Site-directed drug
delivery with biodegradable microspheres. Proceed. Intern. Con/ on

Advances in Controlled Delivery (Baltimore, MD). 30-31 (1996).
19.

N. H. Shah, A. S. Railkar, F. C. Chen, R. Tarantino, S. Kumar, M.
Murjani, D. Palmer, M. H. Infeld, and A. W. Malick. A biodegradable
injectable implant for delivering micro and macromolecules using
poly(lactic-co-glycolic)

acid (PLGA) copolymers. Journal oj"Controlled

Release. 27: 139-147 (1993).
20.

T. Kissel, Y. X. Li, C. Volland, S. Garich, and R. Koneberg. Parenteral
protein delivery systems using biodegradable polyesters of ABA block
structure, containing hydrophobic poly(lactide-co-glycolide)

117

A blocks and

hydrophilic poly(ethylene oxide) B blocks. Journal of Controlled Release.
39: 315-326 (1996).

21.

A.-C. Cheng and R. K. Gupta. Stabilization of tetanus toxoid in poly(DLlactic-co-glycolic acid) microspheres for the controlled release of antigen.

Journal of Pharmaceutical Sciences. 85, 2: 129-132 (1996).
22.

R. Bodmeier and 0. Paeratakul. Plasticizer uptake by aqueous colloidal
polymer dispersions used for the coating of solid dosage forms.

International Journal of Pharmaceutics. 152: 17-26 ( 1997).

I 18

Figure I-Schematic representation of the novel in situ PLGA microsphere
formation process
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Figure 2-Transformation of the PLGA micro globules into microspheres
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Figure 3-Controlled release of different drugs from in situ formed PLGA
microspheres
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Figure 4a-Effect of PEG 400 concentration on the controlled release and
percentage encapsulation efficiency of cytochrome c (PEG 400 concentration
expressed as different ratios of PLGA-triacetin/PEG 400)
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Figure 4b-Effect of cytochrome c concentration on its controlled release and
percentage encapsulation efficiency (cytochrome c concentration expressed as %
w/w of PEG 400)
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Figure 5-Controlled release of myoglobin from in situ formed PLGA
microspheres prepared from NDDS containing different concentrations of the
hydrophilic excipient, mannitol (mannitol concentration expressed as % w/w of
myoglobin-PEG 400 solution)

100
90
(1)
(/)

ro
(1)

~
C

:a
0
c,
0

80
70
60

>,

E

c 50
e 40
(1)
(1)

C.

(1)

-~ 30
1§

-+-no

:::,

E
:::,

mannitol

----1.41

20

---.-2.78

(.)

~5.4

10
0
0

2

4

6

8

Time (Days)

124

10

12

14

16

Figure 6a-Controlled release of myoglobin from in situ formed PLGA
microspheres prepared from NDDS containing different plasticizers
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Figure 6b-Controlled release of myoglobin from in situ formed PLGA
microspheres prepared from NDDS containing different oils

,,

100
90
Q)

IJJ

rn

80

Q)

~
C:

i:i
.2

Cl
0
>,

E

c

70
60
50

Q)

u

ai
a. 40
Q)

>

~

30

E
::,

20

:5
(.)

[-+-Miglyol
10

-

812

Soybean Oil

0
0

2

4

6

8
10
Time (Days)

126

12

14

16

Figure ?a-Effect of formulation and process conditions on the physical stability of
the encapsulated myoglobin
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Figure 7b-Effect of 15 days/4° C storage condition on the physical stability of the
encapsulated myoglobin
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MANUSCRIPT IV

COMPARISON OF VARIOUS INJECTABLE PROTEIN LOADED
BIODEGRADABLE PLGA DEVICES: IN SITU FORMED
IMPLANT V/S IN SITU FORMED MICROSPHERES
V/S ISOLATED MICROSPHERES
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ABSTRACT

Controlled delivery of a model protein, cytochrome c from various
biodegradable devices prepared from the copolymer poly(lactide-co-glycolide)
(PLGA) by a novel, modified microencapsulation process is described here. This
method which did not involve any use of unacceptable organic solvents, but
utilized acceptable vehicle mixture instead, produced in situ formed microspheres
(Jain et. al., a,b). The modification of this novel process yielded different
syringeable mixtures. These on injection, came in contact with water from
aqueous buffer or physiological fluid and as a result, they hardened to form solid
matrix type implant or microspheres (in situ formed implant or microspheres
respectively) entrapping cytochrome c. This modifies method can also be made
to produce injectable, isolated microspheres. These devices exhibited different
characteristics in terms of in vitro cytochrome c release profile, percentage
cytochrome c encapsulation efficiency, and particle size. Thus this novel,
modified microencapsulation process is versatile and it can produce various drug
loaded injectable biodegradable PLGA devices having different characteristics.
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INTRODUCTION
The copolymer of lactide and glycolide referred to as poly(lactide-coglycolide) (PLGA) has been fabricated into various devices like microparticles,
nanoparticles, implants, and films to carry a variety of drug classes ( Jalil and
Nixon, 1990; Tice and Tabibi, 1991; Wu, 1995a,b; Lewis, I 990; Heller, 1980;
Heller, 1984; Heller, 1985; Tice and Cowsar, 1984; Arshady, 1991; BrannonPeppas, 1995; Kitchell and Wise, 1985; Cohen et. al., 1994; Vert, 1996; Zhao and
Leong, 1996; Eldridge et. al., 1993; Tice et. al., 1996). The drug release from the
PLGA device is a combination of the following two mechanisms ( Jalil and
Nixon, 1990; Tice and Tabibi, 1991; Wu, l 995a,b): diffusion through the matrix
and its hydrolytic degradation (which is controlled

b§factors

like PLGA

molecular weight, crystallinity, and lactide:glycolide ratio).
There is a particular interest in controlled delivery of macromolecules such
as peptides and proteins through PLGA microspheres (Lewis, 1990). Although a
wide variety of pharmacologically useful peptide and protein based drugs have
been recently developed by genetic engineering, their therapeutic use is restricted
due to certain disadvantages: (Wu, 1995b; Lewis, 1990): (1) on oral consumption
they are subject to attack by the acidic and enzymatic environment in the stomach
and the enzymes from the brush border membrane of the intestine, (2) their high
molecular weight and size impede their effective transport across the
gastrointestinal membranes, and (3) they have a short biological half-life and on
injection they are quickly metabolized and eliminated. To achieve sustained
blood levels of these drugs, minimize their denaturation or degradation, and to
extend their biological half-life, their delivery by entrapment in PLGA devices has
become an interesting approach (Wu, 1995b; Lewis, 1990). The release of
proteins from these devices is associated with formation of pores and they
increase in number and size as the PLGA degradation proceeds, resulting in
subsequent faster release rates of the protein (Wu, 1995b ).
Shah et al. (1993) and the researchers at Atrix Laboratories, Inc. (Fort
Collins, CO) (Dunn et. al., 1995a,b; Frank et. al., 1994; Dunn et. al., 1994; Lowe
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et. al., 1993; Dunn et. al., 1992; Tipton et. al., 1992; Dunn et. al., 1991) have
described a novel implant system which is parenterally administered as a liquid
and subsequently solidifies into a gel matrix (implant) in situ, from which the
drug is released in a controlled manner. We have previously described the in situ
formation of microspheres by a novel microencapsulation process, which was
based on the principle of phase separation (coacervation) (Jain et. al., a,b). This
method produced PLGA microglobules ("premicrospheres" or "embryonic
microspheres") which on coming in contact with water, hardened to form discreet
PLGA microspheres (in situ formed microspheres), releasing cytochrome c in a
controlled fashion. Various formulation variables affected the characteristics of
this system (Jain et. al. a,b). Also the formulation, profess, and the 15 days/4° C
storage conditions did not affect the physical stability of the encapsulated
cytochrome c.
Here we report a modified version of the above novel microencapsulation
process, which besides producing injectable in situ formed microspheres, can also
be made to yield injectable in situ formed implant or isolated microspheres (Fig.
1). The heme protein, cytochrome c was encapsulated by these three devices and
their characteristics with respect to in vitro cytochrome c release, percentage
cytochrome c encapsulation efficiency, and particle size were compared.

MATERIALS
All the chemicals/reagents were used as purchased. Polyvinyl alcohol
(PVA) (87.0-89.0% partially hydrolyzed, molecular weight: 11,000-31,000) from
J. T. Baker (Phillipsburg, NJ); sodium azide and bovine heart cytochrome c
(molecular weight: 12, 327) from Sigma Chemical Co. (St. Louis, MO); PLGA
RESOMER grade RG 502 H from Boehringer Ingelheim (Ingelheim, Germany);
triacetin from Eastman Fine Chemicals (Rochester, NY); polyethylene glycol 400
(PEG 400) from Union Carbide Corporation (Danbury, CT); miglyol 812 from
HUis America, Inc. (Piscataway, NJ); Span 80 and Tween 80 from LC.I.
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(Wilmington, DE); methylene chloride, n-hexane, and 2-propanol from Fisher
Scientific (Fair Lawn, NJ).

METHODS
Preparation of injectable PLGA implant system

PLGA was dissolved in triacetin by magnetic stirring and heating to
approximately 65° C in a glass vial. The solution was cooled under ambient
condition and to it was added a solution of cytochrome c in PEG 400. This
mixture was magnetically stirred for 5 min followed by additon of Tween 80 and
further stirring for 5 min to form the injectable in situ implant system (Oil Phase
1). The ability of this system to form an implant i/situ was performed in an
aqueous phosphate buffer The system in 1 ml quantity was injected in IO ml of
10 mM, 7.4 pH aqueous phosphate buffer contained in a 20 ml capacity glass vial.
The phosphate buffer also contained 0.02% w/v PVA as an anti-adherent and
0.02% w/v sodium azide as a preservative (bacteriostatic).

Preparation of injectable, stable dispersion of PLGA microglobules

Span 80 was dissolved in miglyol 812 in a glass vial to form Oil Phase 2.
Oil Phase 1 was added dropwise to Oil Phase 2 with continuous homogenization
at 10,000 rpm, using a Biohomogenizer (Biospec Products Inc., Bartlesville, OK)
for a period of 4 min, to form the injectable, stable dispersion of PLGA
microglobules [in a continuous phase consisting of triacetin, PEG 400 and
miglyol (and stabilized by Tween 80 and Span 80)].. The ability of this system to
form microspheres in situ was performed in an aqueous phosphate buffer The
system in 1 ml quantity was introduced in 10 ml of 10 mM, 7.4 pH aqueous
phosphate buffer contained in a 20 ml capacity glass vial. The phosphate buffer
contained PV A and sodium azide.

Preparation of injectable, isolated PLGA microspheres
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The injectable dispersion of PLGA microglobules from above was added
dropwise to a continuously stirred (700 rpm), 2 L I% PV A solution to harden the
microglobules into microspheres.

These were then subjected to vacuum filtering

using a 30 µm Whatman filter paper. The microspheres were then washed with
500 ml of distilled water. This was followed by washing twice with I 00 ml of nhexane:iso-propanol

(I: 1) and further washing with I 00 ml of distilled water

(twice). The isolated microspheres were finally dried for 24 hr in a 282A lsotemp
vacuum oven from Fisher Scientific.

Optical microscopy
The various injectable biodegradable PLGA ~evices were documented
using an Aristomet light microscope (Leitz, Germany) attached to a Kodak
Megaplus camera. The devices were observed using color optics and the
micrographs developed using the Photoshot software from Adobe Systems, Inc.
(San Jose, CA).

In vitro cytochrome c release study
The glass vials containing the in situ formed devices were subjected to
agitation at 100 rpm at 37° Cina 024 Environmental Incubator Shaker from New
Brunswick Scientific Co., Inc. (Edison, NJ). The isolated microspheres were
suspended in the phosphate buffer and agitated in a similar manner. Sai11ples in l
ml aliquot from each vial were withdrawn at predetermined time intervals using a
0.5 µm filter (Millipore Products Division, Bedford, MA) assisted 180 I needle/I
cc plastic syringe assembly (Beckton Dickinson & Co., Rutherford, NJ). The
vials were replenished with I ml of fresh aqueous phosphate buffer by passing it
through the same filter assisted needle/syringe assembly. The amount of
cytochrome c released from the devices into the aqueous phosphate buffer was
quantitatively determined by its absorbance at 409 nm using a UV- Vis
Spectrophotometer from Varian (Varian Australia Pty. Ltd.). A standard
concentration curve was used to determine the concentration of cytochrome c in
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the sample vials. The results were reported as mean of two experiments and for
each experiment the mean of three sample analysis were determined.

Percentage cytochrome c encapsulation efficiency study
The vials containing the in situ formed devices were transferred to plastic
centrifuging tubes, which were then centrifuged at 10,000 rpm for IO min using a
Hermie Z382K centrifuging machine from Denville Scientific, Inc. (Metuchen,
NJ). The devices were washed twice, each time with 5 ml of n-hexane:2-propanol
(1:1). This was then followed by washing with 5 ml of distilled water (twice).
The tubes were then dried for 24 hr under vacuum and the weight of the dried
PLGA microspheres determined. This was follofed by addition of 5 ml of
methylene chloride to the tubes to dissolve the PLGA copolymer and subsequent
extraction of the cytochrome c into 5 ml of distilled water. This step was also
followed for isolated microspheres. The amount of cytochrome c in the aqueous
phase was quantitatively determined by its absorbance at 409 nm. The percentage
encapsulation efficiency was calculated by relating the practical cytochrome c
entrapment to the theoretical cytochrome c entrapment,
Practical cytochrome c entrapment(% w/w)/Theoretical cytochrome c entrapment
(% w/w) x 100

The results were reported as mean of two experiments and for each experiment the
mean of three sample analysis were determined.

Particle size study
The vials containing the in situ formed PLGA microspheres were
subjected to vacuum filtering, followed by washing and drying of the
microspheres as before. The particle size of these isolated microspheres were then
compared to the actual isolated microspheres using a Master Sizer X from
Malvern Instruments, Inc. (Southborough, MA). The microspheres were first
suspended in I 00 ml of distilled water (containing I% Tween 80) and subjected to
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sonication for 30 sec and vortex mixing for 10 sec before analysis. The volume
average particle size of three scans for each sample was reported.

RES UL TS AND DISCUSSION

Formation of the various injectable biodegradable PLGA devices

The novel microencapsulation process on modification formed in situ
implant or microspheres or isolated microspheres (Figs. 1). The mechanism of in
situ implant formation was the same as described by others (Shah et al., 1993;

Dunn et. al., l 995a,b; Frank et. al., 1994; Dunn et. al., 1994; Lowe et. al., 1993;
Dunn et. al., 1992; Tipton et. al., 1992; Dunn et. al., 1991). A parenterally
administered liquid on coming in contact with water1rom aqueous buffer or
physiological fluid, solidifies into a gel matrix (implant) in situ, entrapping
cytochrome c (Fig. 1). PLGA is a hydrophobic polymer and it precipitates in
presence of water, thereby causing the matrix to harden. The optical micrograph
of the in situ formed implant confirms its gel matrix structure (Fig. 2a).
We have previously described the in situ formation of microspheres which
was based on the principle of coacervation (Jain et. al. a,b) (Figs. I and 2). This
method formed PLGA microglobules which on coming in contact with water,
hardened to form discreet PLGA microspheres (in situ formed microspheres) (Fig.
1). Cytochrome c was then released from these microspheres in a controlled
fashion (Jain et. al. a,b). The optical micrograph of the in situ formed
microspheres are shown in Fig. 2b.
The PLGA microglobule dispersion on injection into an aqueous PY A
solution (with constant stirring) lead to the loss in integrity of the dispersion and
rapid hardening of the PLGA microglobules into microspheres (Fig. 2). These
were then isolated by washing and drying (Fig. 1). These microspheres e~hibit a
dense and rigid matrix structure and are smaller than the in situ formed
microspheres (Fig. 2c ).

Percentage cytochrome c encapsulation efficiency and particle size studies
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As depicted in Table I, the in situ formed implant exhibits the lowest
percentage cytochrome c encapsulation efficiency. There is a lag period between
the injection of the liquid implant system and the actual formation of the implant.
During this period, a significant amount of the drug is released into the aqueous
buffer, leading to poor encapsulation efficiency (Table I). The PLGA
microglobules when injected into the aqueous PVA solution (while stirring),
cause rapid extraction of the vehicles and subsequent faster hardening of the
microglobules into microspheres. Thus, not much drug is lost and the isolated
microspheres exhibit an excellent encapsulation efficiency (Table I). For the in
situ formed microspheres, the extraction of the vehicle mixture is gradual. There

is transportation of the cytochrome c to the external a(ueous buffer during the
hardening of the PLGA microglobules, leading to some loss of cytochrome c
(Table I). The isolated PLGA microspheres are produced relatively faster than the
in situ formed microspheres and hence they are smaller in size as compared to the
in situ formed microspheres (Table I).

In vitro cytochrome c release study
A strong burst (amount of cytochrome c released by the end of day I) was
observed for the in situ formed implant (Figure 3). This is chiefly due to the high
concentration of unencapsulated cytochrome c as a result of low percentage
encapsulation efficiency (Table I). The burst could also be due to dissolution of
cytochrome c attached to the implant surface. The in situ formed implant
exhibited the fastest release of cytochrome c (Figure 3). The isolated
microspheres exhibited the lowest burst and this is due to the absence of the
unencapsulated cytochrome c (Figure 3). Also they showed the slowest drug
release (Figure 3). This could be attributed to the rigid and dense nature of their
matrix which permited slow release of cytochrome c. The in situ formed PLGA
microspheres have a relatively low percentage encapsulation efficiency than the
isolated microspheres (Table I) and hence they exhibit relatively higher burst
effect. Also they are relatively more porous than the isolated microspheres,
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therby exhibiting a relatively faster cytochrome c release than the isolated
microspheres (Figure 3).

CONCLUSION
Controlled delivery of cytochrome c from the various biodegradable
PLGA devices prepared by a novel, modified microencapsulation process is
described here. The method produced different syringeable mixtures, which on
injection formed solid matrix type implant or microspheres (in situ formed
implant or microspheres respectively) entrapping cytochrome c. The process can
also be made to yield injectable, isolated microspheres. The burst effect from
these devices exhibited the following trend: in situ1ormed implant> in situ
formed microspheres > isolated microspheres. The in situ formed microspheres
were larger in size than the isolated microspheres. Also, the isolated microspheres
exhibited the slowest controlled release of cytochrome c, while the in situ formed
implant exhibited the fastest. Thus, this novel, modified microencapsulation
process is versatile and it can produce various drug loaded injectable
biodegradable PLGA devices having different characteristics.
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Figure I-Schematic representation of the novel modified microencapsulation
process to produce various injectable biodegradable PLGA devices
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Figure 2a-Optical micrograph of the in situ formed PLGA implant
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Figure 2b-Optical micrograph of the in situ formed microspheres
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Figure 2c-Optical micrograph of the isolated microspheres
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Table I-Percentage cytochrome c encapsulation efficiency and particle size studies
of the various injectable biodegradable PLGA devices

Injectable biodegradable

Percentage cytochrome c

PLGA device

encapsulation efficiency

Particle size (µm)

In situ formed implant

52.8

-

In situ formed

74.5

98.6

90.3

84.3

microspheres
Isolated microspheres

i
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Figure 3-In vitro cytochrome c release from various injectable biodegradable
PLGA devices
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CONCLUSION AND FINAL REMARKS

The salient features of the novel microencapsulation process and the drug
delivery sytem described in this research project are as follows:

(I)

The sytem excluded the use of unacceptable organic solvents like
methylene chloride and used acceptable vehicle mixture instead to prepare
biodegradable PLGA microspheres.

(2)

The sytem formed drug containing PLGA microglobules
("premicrospheres" or "embryonic micfospheres") which could be
considered as precursors to the final microsphere product; these on corning
in contact with water hardened to form discreet PLGA microspheres (in

situ formed microspheres) which subsequently exhibited non-variable,
predictable, and controlled drug release profile.

(3)

Unlike the traditional methods, this system precluded the need for
reconstitution of the PLGA microspheres as they are formed in situ.

(4)

Various formulation varibles affected the characteristics of this system.

(5)

The formulation and process conditions did not adversely affect the
physical stability of the encapsulated protein drugs.

(6)

Besides in situ forming microspheres, the novel rnicroencapsulation
method can be modified to produce in situ formed implant or isolated
microspheres; these drug loaded devices exhibited different characteristics.

(7)

This research project makes a significant overall contribution to the
knowledge of the underlying theoretical principles of drug delivery
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•
through biodegradable devices and in particular, problems associated with
protein drug delivery.

(8)

The novel nature of the system provides a high probability that a patent
application would be filed.
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